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Chapter 1
Introduction
1.1 Background
1.1.1 The Human Immune System
Throughout evolution, humans and all their ancestors had to fight infection with different,
similarly evolving pathogens in order to survive. Over time, a very powerful system de-
veloped to protect our tissue from the danger of invading microbes, virus-infected cells, or
tumor cells. To achieve this protection, the immune system has to be able to distinguish
between self and non-self, mounting a destructive response only against foreign microbes
and malignant cells while keeping healthy tissue intact. Excess activation of the immune
response can have disastrous consequences as autoimmune diseases illustrate. Therefore,
precise recognition and a fine-tuned modulation of the triggered signal is necessary.
1.1.2 Innate and Adaptive Immunity
How does the immune system achieve powerful protection and precise modulation?
The immune system can be divided into two branches: innate and adaptive immunity.
The innate immune system was discovered as the first line of defense comprised on the
cellular level of phagocytes like macrophages and neutrophils which effectively ingest and
kill invading microbes [1].
Adaptive immunity is executed by lymphocytes that acquire highly specific antigen recep-
tors through somatic rearrangement and hypermutation and clonal selection. Lymphocytes
include CD4+ and cytotoxic T cells as well as B cells that turn into antibody producing
plasma cells. Their selected receptors, each specific for one antigen, are stored for reacti-
vation in the form of B and T memory cells.
Both branches were thought of as independent systems at first, one being unspecific and the
other specific and generally sequential in order, until evidence suggested a costimulatory
signal is necessary for lymphocytes to be activated [2].
In 1989, Charles Janeway proposed that conserved microbial products activating germline
encoded receptors induce this costimulatory signal [3].
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This pattern recognition theory was substantiated by the discovery of Toll-like receptors
(TLRs) which both induce cytokines [4] and react to microbial stimuli [5]. Over the
years, many more pattern recognition receptors (PRRs) that recognize so-called pathogen
associated molecular patterns (PAMPs) were described [6]. These PRRs activate signaling
cascades that lead to the production of inflammatory cytokines and chemokines. These
in turn induce an anti-microbial response in both immune and non-immune cells. As a
result, depending on the activated innate PRRs, different PAMPs initiate different types
of adaptive response and modulate their magnitude and duration [7].
1.1.3 Cytokines and Interferons
Cytokines as Mediators of Immunity
Cytokines comprise a heterogeneous group of small proteins that are secreted by immune
or non-immune cells to mediate an inflammatory reaction.
This reaction includes the induction of fever necessary to efficiently fight infection and
protect host tissue. Induction of fever is mainly mediated by tumor necrosis factor-alpha
(TNFα), interleukin (IL)-1, and IL-6. These cytokines also initiate the so-called acute-
phase response which involves the production of inflammatory effector proteins in the
liver, especially in response to bacterial infection. Acute-phase proteins like C-reactive
protein (CRP) mimic the actions of antibodies, such as opsonization and complement
activation, but have a broad specificity and require only cytokines for their production.
TNFα, IL-1, and IL-6 also mobilize neutrophils from bone marrow to ingest (phagocytose)
microbes, mobilize energy from fat and muscle cells to fight infection and induce dendritic
cell maturation.
TNFα is produced by macrophages, natural killer cells (NK cells) and T cells to promote
inflammation and endothelial activation. It triggers local containment of infection, but can
also induce shock when released systemically.
IL-1 is secreted by macrophages and epithelial cells. It enables leukocyte transmigration
and induces T cell and macrophage activation.
IL-6 is secreted by T cells, macrophages and endothelial cells and can, among other func-
tions, induce T and B cell growth and differentiation.
Binding of interleukins to their receptors activates the JAK-STAT signal transduction
pathway. This involves tyrosine kinase Janus kinases (JAKs)-mediated dimerization of
signal transducer and activator of transcriptions (STATs) and their translocation to the
nucleus, where they activate transcription of target genes [8].
As viruses use their host’s replication machinery to replicate within host cells, a specific
type of immune response is necessary to restrain infection. In mammals, birds and fish,
interferons, aptly named for their ability to interfere with the viral replication cycle, play
a major role for this response [9].
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Antiviral Immunity and the Interferon System
Interferons can be separated into three groups; type I, II, and III IFNs.
The group of type I IFNs consists of several subtypes of interferon-α (IFN-α) and one
interferon-β (IFN-β) and is expressed ubiquitously upon viral infection, for example in
fibroblasts and epithelial cells. Leukocytes, especially plasmacytoid dendritic cells (pDCs),
are responsible for producing systemic levels of IFN-α [10].
The three type III IFNs called interferon-λ (IFN-λ), IL-28A, and B are also ubiquitously
expressed upon viral infection, their respective receptors being limited to specific tissue
types [10].
Figure 1.1: Type I IFN Induction by Different PAMPs
Viral pathogen associated molecular patterns or synthetic analogues induce interferon expression by
binding to cytosolic receptors or Toll-like receptors on the cell surface or in endosomes (adapted from
[10]).
Type I interferons are induced by PAMPs, especially by viral nucleic acids or their synthetic
analogues (Figure 1.1).
Type II IFNs include only interferon-γ (IFN-γ), which is expressed by T cells and NK cells
upon activation of their antigen receptor and stimulation with IL-12 and IL-18 [10].
For IFN-α and -β, induction requires signaling via IFN regulatory factor (IRF)-3 and
-7. While IRF-3 is constitutively expressed at low levels, IRF-7 is induced by IFN-β,
establishing a positive feedback loop of type I interferon induction [11] (Figure 1.2, right).
Both type I IFNs bind to the ubiquitously expressed dimeric IFN-α receptor (IFNAR).
When assembled, IFNAR brings two Janus tyrosine kinases called JAK-1 and tyrosine
kinase (TYK)-2 in close proximity so they phosphorylate each other as well as the tran-
scription factors STAT-1 and -2. These transcription factors associate with IRF-9 to
form a complex called interferon stimulated gene factor (ISGF)-3. This transcription
factor translocates into the nucleus and activates transcription of interferon stimulated
genes (ISGs) by binding to the interferon stimulated responsive element (ISRE) in their
promoter region [12] (Figure 1.2, left).
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Figure 1.2: Type I Interferon Synthesis and Signaling
PAMPs induce IFN-α and -β via IRF-3 and -7. Both activate the IFN-α receptor and signal via a
JAK/STAT-pathway to induce hundreds of ISGs to generate an antiviral state. Among these ISGs are
antiviral signaling proteins like TLRs, RLHs and IRF-7 to boost viral recognition as well as antiviral
effector genes like PKR and OAS. Pink boxes indicate points of viral interference (adapted from [13]).
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Effects of Type I Interferons
There are hundreds of ISGs mediating the diverse context-specific effects of interferons. In
uninfected cells without costimulation by PRRs, an antiviral state is induced to prevent
the spread of infection. In infected cells, tumor suppressor p53 and other mechanisms
induce apoptosis [14] and suppress proliferation [15].
The antiviral state includes upregulation of antiviral signaling proteins like TLRs, RIG-I-
like helicases and IRF-7 to promote viral recognition [10]. Other ISGs are antiviral effector
proteins like the myxovirus resistance (Mx) family, ISG20, OAS, or PKR (Figure 1.2,
middle).
Mx proteins detect and bind viral nucleocapsid proteins, rendering them unavailable for
viral replication [16].
OAS is activated by double-stranded RNA (dsRNA) and in turn activates the endori-
bonuclease RNase L, which cleaves viral genomic and messenger RNA as well as cellular
messenger RNA (mRNA). This cleavage blocks viral replication, produces immunogenic
stretches of ribonucleic acid (RNA) and even induces apoptosis [17].
Similarly, ISG20 is an exonuclease which cleaves single-stranded RNA (ssRNA) [18].
dsRNA activates PKR, which inhibits translation of viral and cellular mRNA and induces
apoptosis [19].
In addition to these cell-intrinsic effects, type I IFNs have diverse effects on adaptive
immune cells when combined with signaling via T cell receptor (TCR) or TLRs. In this
context, they regulate NK cell and cytotoxic T cell function, thereby aiding the elimination
of infected cells, and facilitate presentation of viral antigens to cytotoxic T cells by dendritic
cells [15].
Viral Evasion Strategies
Viruses inhibit IFN signaling in a variety of ways. They can minimize stimulation of
PRRs, block IFN induction, signaling or ISG activity, and even block host gene expression
or protein synthesis altogether [20].
For example, influenza A virus NS1 protein inhibits IFN induction by sequestration of
dsRNA [20], and rotavirus NSP1 protein degrades IRF-3 [21]. Vesicular stomatitis virus
(VSV) matrix (M) protein blocks transcription unless a point mutation attenuates it, in
which case efficient IFN production is restored [22]. Poxviruses secrete soluble IFN-binding
proteins [23], rabiesvirus P protein inhibits STAT-1 and -2 [24], and Herpes simplex virus-1
protein US11 inhibits PKR [25].
The numerous strategies viruses have evolved to impede with the IFN response underline
its importance for the infected host.
In conclusion, type I interferons are essential mediators linking innate and adaptive im-
munity for the eradication of viruses. Their induction by PRRs is discussed in the next
section.
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1.1.4 Pathogen Recognition by the Innate Immune System
The heterogenous group of PRRs can be divided into membrane-bound and cytoplasmic
receptors.
Membrane-bound PRRs include the family of TLRs, which can be found on both the
outer cell membrane and the endosomal membrane. TLRs can recognize both extracellular
and endocytosed pathogens. Since they identify a wide range of pathogens, they play an
important role in the activation of both innate and adaptive immune responses.
C-type lectin receptors (CLRs) comprise soluble and transmembrane proteins expressed by
myeloid cells that can recognize pathogenic carbohydrate structures and danger-associated
self molecules [26].
Cytoplasmic PRRs include NOD-like receptors (NLRs), which recognize different bacterial
components [27], and cGAMP synthase (cGAS), which recognizes deoxyribonucleic acid
(DNA) [28], and RLHs.
1.1.5 Toll-like Receptors and their Signaling
The family of TLRs comprises ten members in the human genome, nine of which are
conserved in both humans and mice and have been well described, namely TLR1-9. They
recognize a wide variety of bacterial, viral, fungal and protozoal compounds, a selection of
which is summarized in table 1.1. Both their structure and activation process have been
described in much detail. While TLR1, 2, 4, 5, and 6 reside on the cell surface, where they
recognize PAMPs from bacteria, fungi, and protozoa and induce mainly inflammatory
cytokines, TLR3, 7, 8, and 9 recognize mainly nucleic acid PAMPs from viruses and
bacteria and are able to induce type I interferons in response to activation by their ligands
[29].
When activated by their respective ligand, TLRs signal by recruiting different TIR-domain
containing molecules which comprise myeloid differentiation factor 88 (MyD88), MyD88-
adaptor like (MAL), TIR-domain-containing adaptor protein inducing IFN-beta (TRIF)
and TRIF-related adaptor molecule (TRAM). These adaptor molecules activate a signaling
cascade that culminates in the activation of transcription factors like nuclear factor kappa
B (NF-κB), IRF-3 and -7 and mitogen-activated protein kinases (MAPKs). NF-κB and
MAPK induce a large number of inflammatory cytokines like IL-6, IL-12p40 and TNFα.
IRF-3 and -7 collaborate with NF-κB in the induction of type I interferons [29].
1.1.6 The Family of RIG-I-like Helicases
While TLRs and CLRs are only expressed in specialized immune cells, RLHs are ubiqui-
tously expressed and enable non-immune cells to combat viral infection.
RIG-I, melanoma-differentiation-associated protein 5 (MDA5), and laboratory of genetics
and physiology 2 (LGP2) form the family of RLHs.
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TLR ligand origin
TLR1/2 triacyl lipopeptides bacteria, mycobacteria, mycoplasma
TLR2 peptidoglycan gram-positive bacteria
lipoarabinomannan mycobacteria
alkylacylglycerol, lipophosphoglycan protozoa
TLR2/dectin-1 β-glucans fungi
TLR3 ssRNA, dsRNA viruses
poly(I:C) RNA synthetic
TLR4 LPS gram-negative bacteria
glycoinositolphospholipids protozoa
TLR4/CD14 glucuronoxylomannan fungi
TLR5 flagellin flagellated bacteria
TLR6/2 diacyl lipopeptides mycoplasma
lipoteichoic acid gram-positive bacteria
TLR7 ssRNA viruses, bacteria
R848 synthetic
TLR8 ssRNA, dsRNA RNA viruses
R848 synthetic
TLR9 DNA with unmethylated CpG motifs viruses, bacteria, protozoa
Table 1.1: TLRs and Their Ligands
Structure and Activation of RLHs
The structure and activation process of RIG-I were recently uncovered in more detail by
crystallography. RIG-I is a large multidomain protein containing a DExD/H box RNA
helicase domain and a C-terminal domain (CTD) connected via bridging helices [30]. Two
caspase-recruitment domains (CARDs) required for downstream signaling make up the N-
terminus. MDA5 and LGP2 share a similar structure, except that LGP2 lacks the CARDs.
Lacking CARDs, LGP2 has been proposed as both a negative and a positive regulator of
RIG-I and MDA5 signaling in different experimental settings [31, 32].
In order to efficiently detect viral RNA among an abundance of cellular or host RNA,
binding of RIG-I or MDA5 requires characteristics unique to viral RNA. MDA5 is activated
by long viral dsRNA or its synthetic analog polyinosinic:polycytidylic acid (poly(I:C))
[33]. The properties of synthetic or viral RNA to activate RIG-I have been the subject
of extensive research. The minimal requirement seems to be a blunt-ended base-paired
oligonucleotide of 10-20 base pairs (bps) with a 5’triphosphate. Some longer (>200bp)
dsRNAs seem to bind as well, even without a triphosphate end, possibly by translocation
of RIG-I along the RNA strand [30]. Host RNA is usually single-stranded and further
secured from recognition by RIG-I through addition of a cap at the 5’-end before it is
exported from the nucleus into the cytosol.
In the absence of a ligand, RIG-I is in an auto-repressed state characterized by an open
and flexible conformation. Only the two CARDs form a rigid unit with the inner CARD
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attached to the helicase domain (Figure 1.3). The CTD is flexibly linked to the helicase
domain and free to bind its RNA ligand with high affinity.
Once it binds the RNA, it induces the closed conformation of the RIG-I molecule in
which the helicase domain cooperatively binds the RNA strand and adenosine triphos-
phate (ATP). The tandem CARDs are released and become accessible for downstream
signaling, but also for ubiquitination. Once they are ubiquitinated by tripartite motif E3
ligase (TRIM25) [34], reversion to the repressed state is blocked even if ATP is hydrolyzed
or removed [30] (Figure 1.3).
Figure 1.3: RIG-I Structure and Activation
The RIG-I molecule comprises a helicase domain, a CTD and two N-terminal CARDs attached to the
helicase domain. Upon binding of triphosphate RNA and ATP, the CTD binds the 5’ triphosphate
containing end and, together with the helicase domain, binds the RNA. The CARDs are released from
their binding to the helicase domain to activate downstream signaling (adapted from [30]).
Different viruses are differentially recognized by RIG-I and MDA5. While paramyxoviruses,
VSV, influenza virus as well as the flaviviruses Japanese encephalitis virus and hepatitis C
virus are recognized by RIG-I, picornaviruses such as encephalomyocarditis virus (EMCV)
and Theiler’s virus are sensed via MDA5 [35].
RIG-I has also been found to recognize RNA transcribed from viral DNA by cellular RNA
polymerase III, thus it is able to sense not only RNA viruses, but also DNA viruses like
Epstein-Barr virus (EBV) [36].
Signaling of RLHs
Upon activation by their respective ligand, RIG-I and MDA5 bind via homotypic CARD-
CARD interaction to mitochondrial antiviral signaling protein (MAVS), also known as
IPS1, Cardif, or VISA. MAVS is a transmembrane protein in the outer mitochondrial
membrane that also contains a CARD on the cytosolic side. Intact mitochondrial function
including a stable membrane potential ∆Ψm is necessary for MAVS signaling to occur [37]
(Figure 1.4).
1.1 Background 9
MAVS recruits TNF-receptor-associated factor (TRAF) family members TRAF2, 3 and 6.
TRAF3, in concert with NF-κB essential modulator (NEMO), activates a kinase complex
comprising of two kinases named TANK-binding kinase 1 (TBK1) and inducible IαB kinase
(IKK). These two kinases can phosphorylate IRF3 and 7, resulting in their formation of
homo- or heterodimers and translocation to the nucleus, where they induce the expression
of type I interferon (Figure 1.4, right).
TRAF2 and 6 activate a kinase complex composed of IKKα, IKKβ and NEMO, which
phosphorylates the inhibitory protein inhibitor of NF-κBα (IκBα), thereby marking it
for ubiquitin-dependent proteasomal degradation. This loss of inhibition enables the two
NF-κB subunits p65 and p50 to translocate to the nucleus and induce the production of
inflammatory cytokines (Figure 1.4, left).
These seemingly separate pathways leading to induction of type I IFNs and inflammatory
cytokines intertwine. NF-κB is required for the initial induction of IFN-β, which in turn
induces IRF-7 to create a positive feedback loop [38].
1.1.7 Mitochondria
Mitochondria are dynamic organelles that are vital for a wide range of cellular processes in
virtually all eucaryotic cells. In addition to a number of important functions in metabolism
and homeostasis, mitochondria are involved in various signaling cascades, including cell
cycle control, apoptosis, and innate immune signaling [39].
According to the now widely recognized endosymbiotic theory, mitochondria developed
from α-proteobacteria that became incorporated into eucaryotic cells in a symbiotic rela-
tionship [40]. This theory is substantiated by a number of mitochondrial characteristics
that mark their bacterial origin: they possess a double membrane, their own circular
genome, and 70S ribosomes similar to those of bacteria. Mitochondrial DNA encodes 13
proteins of the oxidative phosphorylation complex; however, most of the approximately
1500 proteins in the mitochondrial proteome are encoded in the nucleus [39].
Regulation of Metabolism
Mitochondria are well known for their critical role in providing energy to the cell in the
form of ATP. The energy is transformed by the oxidation of nutrients through the five
complexes of the respiratory chain located in the inner mitochondrial membrane (Figure
1.5). Complex I and II obtain electrons from NADH or FADH2, respectively, and pass them
on to complex III via coenzyme Q (CoQ). Complex III relays them via cytochrome C to
complex IV, where the electrons react with O2 and H
+ ions to form water. This electron
transport chain is coupled to the movement of H+ ions across the inner mitochondrial
membrane at complexes I, III and IV, creating a proton gradient across the membrane.
The energy of this proton gradient is utilized by complex V to phosphorylate adenosine
diphosphate (ADP) to ATP, thus completing the process of oxidative phosphorylation
(Figure 1.5).
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Figure 1.4: RLH-Mediated Signaling
Upon activation by viral RNA, RIG-I and MDA5 associate with MAVS through their CARDs. MAVS
in turn activates TRAF3, which together with NEMO enables TBK1 and IKK- to phosphorylate IRF3
and 7, leading to the expression of type I interferon. TRAF2 and 6 induce inflammatory cytokines via
NEMO, IKKα, IKKβ, and NF-κB ([38], simplified).
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Figure 1.5: Mitochondrial Oxidative Phosphorylation and ROS Generation
Oxidative phosphorylation takes place at the inner mitochondrial membrane complexes I-V. These com-
plexes transfer electrons from NADH or FADH2 onto O2 and H
+, yielding H2O. Complexes I, III, and
IV also expel H+ across the inner membrane, creating a protein gradient that is used by complex V to
create ATP. Superoxide (O2
.−) is produced by complexes I, II, and III and inactivated by mitochondrial
or cytosolic enzymes ([41], simplified).
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reactive oxygen species (ROS) like superoxide (O2
.−) are produced by electron leakage at
complexes I, II, and III (Figure 1.5). They are inactivated by superoxide dismutase (SOD)1
and 2 together with cytosolic catalase and mitochondrial glutathione peroxidase (GPX).
Interestingly, ROS are not merely a toxic byproduct, but have also been found to be tightly
regulated signaling molecules with diverse functions [42].
Nutrient supply regulates metabolic rates [43], but mitochondrial dynamics also seem to
play a role [44]. Mitochondrial dynamics include mitochondrial motility within the cell as
well as two opposite processes called fusion and fission (Figure 1.6). Fusion is regulated
by mitofusin (Mfn)1 and 2, while dynamin related protein 1 (Drp1) achieves fission. Both
Mfn1 and 2 have been implicated in the control of metabolic rates [39].
Figure 1.6: Mitochondrial Dynamics
Mitochondrial fusion and fission and involved mediator proteins (adapted from [45]).
In addition to their role in providing ATP, mitochondria are also involved in calcium
homeostasis and a number of biosynthetical pathways such as the production of amino
acids, lipids, nucleotides, and haem [41].
Mitochondria in Apoptosis and Cell Cycle Control
Mitochondria play a central role in the execution of programmed cell death also called
apoptosis. For apoptosis, cell intrinsic or extrinsic signals activate a signaling network
that recruits a family of cysteine proteases called caspases. These caspases initiate the
breakdown of cells, by a process including DNA condensation and nuclear fragmentation,
cell shrinkage and blebbing [46]. In the extrinsic activation pathway mediated by death
receptors, mitochondria create an amplification loop, whereas in the intrinsic pathway
initiated by cellular deprival or stress, mitochondria are the central regulators [46]. This
regulation is achieved by the translocation of proapoptotic factors of the Bcl-2 family to the
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mitochondria. There, they mediate the release of apoptogenic factors like cytochrome c, a
caspase activator, from the mitochondria into the cytosol [39]. Mitochondrial fragmentation
occurs during cell death, but seems to be a necessary step as well, as inhibiting Drp1 delays
or inhibits cell death [47].
In addition to orchestrating apoptosis, mitochondria are tightly linked to cell cycle control.
Mitochondria fragment before cell division [48]. Conversely, overexpression of Mfn2 not
only stimulates mitochondrial fusion, but also induces cell cycle arrest via a Ras-dependent
pathway [49], while many of the downstream signaling partners are also located at the
mitochondria [39]. Furthermore, low energy conditions characterized by a high adenosine
monophosphate (AMP) concentration induce a p53-dependent cell cycle arrest [50].
A reason for the involvement of mitochondria in several diverse signaling pathways might
be their unique membrane composition. Formation of microdomains by lipid rafts or actin
patches has been hinted to be an essential part of many signaling cascades [39].
Mitochondria in Innate Immunity
Mitochondrial integrity and function is essential for innate immune signaling and effector
functions. The central adaptor protein for RLH-signaling, MAVS, is not only located on the
outer mitochondrial membrane, but the mitochondrial environment seems to be essential
for its function, as cytosolic mislocalization abrogates its signaling function [51].
Upon activation, MAVS self-assembles into large prion-like aggregates on the surface of
the mitochondria that activate IRF-3 and induce assembly in native MAVS proteins [52].
A number of mitochondrial cofactors create the environment essential for MAVS signaling.
For example, translocase of the outer membrane (TOM)70 and heat-shock protein (HSP)90
interact with and enable signaling of MAVS and TBK1 [53]. HSP90 might be necessary
for assembly of MAVS into prion-like structures [52].
In addition to its role in mitochondrial fusion, Mfn2 has been shown to inhibit MAVS
signaling [54]. Mfn1-induced fusion also appears to be necessary for assembling MAVS
signaling complexes, suggesting a role for mitochondrial dynamics in antiviral signaling [55].
Elongation of mitochondria has been shown to occur during RLH signaling. Conversely,
inhibiting fission boosts signaling, while inhibiting fusion stops it [56].
As some viruses replicate near mitochondrial membranes [57], antiviral signaling might
have evolved around mitochondria to be in close proximity of viral replication and thereby
increasing the likelihood to detect viral invasion early [41].
Furthermore, mitochondrial membrane potential has been reported as a requirement for
the activation and signaling of MAVS [37].
The presence of ROS also appears to be a component of efficient signaling [58]. A rise in
cellular ROS, caused by diminished autophagy for example, can augment RLH signaling
[59]
In summary, mitochondria form a unique environment and establish an essential platform
for antiviral signaling.
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1.2 Objectives and Aims
Figure 1.7: Co-Immunoprecipitation and Analysis by Mass Spectrometry
Cells expressing flag-tagged RIG-I were infected with VSV, lysed and immunoprecipitated with anti-
flag antibodies. The eluate was analyzed via mass spectrometry to produce a list of candidate RIG-I
interacting proteins.
In order to identify new factors possibly involved in the RIG-I-dependent detection of viral
infection, our group previously performed immunoprecipitation and subsequent analysis
by mass spectrometry of proteins that co-immunoprecipitated with overexpressed RIG-I-
FLAG in VSV-infected human embryonic kidney 293 (HEK293) cells (Dominik Ho¨chter,
data not shown).
These experiments (Figure 1.7) identified a list of potential RIG-I-interacting proteins.
After eliminating known interactors, known artefacts, and viral proteins, two proteins,
cytokine-responsive protein CR6-interacting factor 1 and RNA binding motif 10 remained
as previously unknown, possibly new interactors of RIG-I.
RBM proteins contain an RNA recognition motif (RRM) which can perform various func-
tions within the cell, like pre-mRNA processing, RNA stability, and translation. RNA
binding motif 10 (RBM10) shows high sequence similarity to RBM5, which has been de-
scribed as a cell cycle regulator. However, further functional data for RBM10 were lacking
thus far [60].
CRIF1 is a functionally elusive protein for which different subcellular localizations and
diverse interacting proteins had been described at the beginning of this project.
CRIF1 was first shown to interact with members of the growth arrest and DNA damage
inducible protein 45 (GADD45) protein family and was therefore suggested to influence
cell cycle progression and cell growth [61].
Further studies suggested a role in cell proliferation [62]. In addition, research found
interactions with nuclear proteins including nuclear receptor 77 (NUR77) [63], androgen
receptor [64], and nuclear respiratory factor 2 (NRF2) [65], thus claiming an essential
1.2 Objectives and Aims 15
role for intestinal development [66]. Furthermore, CRIF1 was suggested to be a specific
coactivator of STAT3 [67].
In preliminary experiments, both proteins had shown antiviral effects. Therefore, the aim
of the present study was to investigate if CRIF1 or RBM10 indeed had a function in
antiviral immunity and if so, by what mechanism. To this purpose, the following questions
were explored:
• Do CRIF1 or RBM10 influence viral infection or cytokine response to infection?
• Are CRIF1 or RBM10 levels influenced by viral infection?
• How can CRIF1 or RBM10 exert an influence on antiviral signaling?
• Do CRIF1 or RBM10 specifically interact with RIG-I?
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Equipment
Technical equipment and instruments used in this study are listed in table 2.1. Reagents
for molecular biology methods are listed in table 2.2, reagents for cell biology methods in
table 2.3, and reagents for biochemical methods in table 2.4.
Plastic material for cell culture was obtained from Greiner (Frickenhausen, D), Falcon (Hei-
delberg, D), Becton Dickinson (Le Pont de Claix, F), Bibby Sterrilin (Stone, Staffordshire,
GB) and Corning (Corning, USA).
Assays and kits used for the described experiments are listed in table 2.5.
Table 2.1: Technical Equipment and Instruments
Instrument Vendor
AlphaImager HP R© Alpha Innotech (San Leandro, CA, USA)
Balance SBC 21 R© Scaltec Instruments (Heiligenstadt, D)
Centrifuge 5415 R R© Eppendorf (Hamburg, D)
FACSCalibur R© flow cytometer BD Biosciences (San Diego, CA, USA)
FACSCanto II R© flow cytometer BD Biosciences (San Diego, CA, USA)
Ice machine Ziegra (Isernhagen, D)
Incubator Heraeus (Hanau, D)
ImageQuant R© biomolecular imager GE Healthcare (Little Chalfont, UK)
Lamin Air R© (HB2448) Heraeus (Hanau, D)
Leica LAS AF R© microscope Leica Microsystems (Wetzlar, D)
LightCycler 480 R© Roche (Basel, CH)
Macrovue 2011 R© transilluminator LKB (Bromma, SE)
Mini centrifuge MCF-2360 LMS (Lo¨wen, B)
Multifuge 3L-R centrifuge Heraeus (Hanau, D)
Multiplate reader Mithras LB940 R© Berthold Technologies (Bad Wildbach, D)
NanoPhotometer R© Implen (Mu¨nchen, D)
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pH meter SB70P sympHony R© VWR (Darmstadt, D)
PowerPac 200 R© Power Supply Bio-Rad (Mu¨nchen, D)
Thermocycler T3 R© Biometra (Go¨ttingen, D)
Thermomixer R© compact Eppendorf (Hamburg, D)
Vortex mixer Janke & Kunkel (Staufen, D)
Water filter Millipore (Schwalbach, D)
Table 2.2: Reagents for Molecular Biology Methods
Reagents Company
Real-time PCR
LightCycler 480 Probes Master R© Roche (Basel, CH)
Reverse transcriptase H- Fermentas (St. Leon-Roth, D)
Universal Probe Library R© rt-PCR probes Roche (Basel, CH)
In-vitro transcription
Chloroform Roth (Karlsruhe, D)
Ethanol Roth (Karlsruhe, D)
Mini quick spin oligo columns Roche (Mannheim, D)
Roti R©-phenol/chloroform/isoamylalkohol Roth (Karlsruhe, D)
Exo-Minus klenow DNA polymerase Fermentas (St. Leon-Roth, D)
Exo-Minus klenow buffer Fermentas (St. Leon-Roth, D)
RNase inhibitor Fermentas (St. Leon-Roth, D)
Gel electrophoresis
Agarose Sigma-Aldrich (Steinheim, D)
Tris acetate Roth (Karlsruhe, D)
Ethidium bromide Sigma-Aldrich (Steinheim, D)
6x loading dye Thermo Fisher (Waltham, MA, USA)
O’GeneRuler R© DNA ladder mix Thermo Fisher (Waltham, MA, USA)
PCR and quick change PCR
Pfu polymerase and buffer Fermentas (St. Leon-Roth, D)
DpnI Fermentas (St. Leon-Roth, D)
Desoxyribonucleotides Fermentas (St. Leon-Roth, D)
Plasmid construction
AscI restriction enzyme New England Biolabs (Ipswich, MA, USA)
FseI restriction enzyme New England Biolabs (Ipswich, MA, USA)
NEBuffer 4 New England Biolabs (Ipswich, MA, USA)
Calf intestine alkaline phosphatase Promega (Madison, WI, USA)
T4 DNA ligase Fermentas (St. Leon-Roth, D)
DH5α Invitrogen (Carlsbad, CA, USA)
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Luria Bertani (LB) broth Roth (Karlsruhe, D)
Potassium acetate (KAc) Roth (Karlsruhe, D)
Manganese chloride (MnCl2) Roth (Karlsruhe, D)
Rubidium chloride (RbCl) Roth (Karlsruhe, D)
Calcium chloride (CaCl2) Roth (Karlsruhe, D)
Morpholinepropanesulfonic acid (MOPS) Thermo Fisher (Waltham, MA, USA)
LB agar Roth (Karlsruhe, D)
Ampicillin Roth (Karlsruhe, D)
Kanamycin Sigma-Aldrich (Steinheim, D)
Table 2.3: Reagents for Biochemical Methods
Reagents Vendor
Immunoprecipitation and western blot
Monoclonal anti-flag antibody clone M2 (mouse) Sigma-Aldrich (Steinheim, D)
Anti-cMYC antibody 9E10 Gentaur (Kampenhout, B)
Rb pAB to RBM10 ab72423 Abcam (Cambridge, UK)
Anti-rabbit IgG, HRP-linked Ab Cell Signaling Technology (Danvers, MA, USA)
Anti-mouse IgG, HRP-linked Ab Cell Signaling Technology (Danvers, MA, USA)
Anti-FLAG M2 Affinity Gel beads Sigma-Aldrich (Steinheim, D)
Ammonium persulfate (APS) Sigma-Aldrich (Steinheim, D)
Beta-mercaptoethanol Bio-Rad (Mu¨nchen, D)
Blotting paper Schleicher & Schuell (Du¨sseldorf, D)
Ethylenediaminetetraacetic acid (EDTA) Roth (Karlsruhe, D)
Glycin Roth (Karlsruhe, D)
Laemmli sample buffer Bio-Rad (Mu¨nchen, D)
Magnesium chloride (MgCl2) Roth (Karlsruhe, D)
Methanol Merck (Darmstadt, D)
Milk powder Roth (Karlsruhe, D)
Prestained protein molecular weight marker Fermentas (St. Leon-Roth, D)
Immobilon-P R© PVDF transfer membrane Millipore (Schwalbach, D)
Rotiphorese R© Gel 30 Roth (Karlsruhe, D)
Sodium chloride (NaCl) Roth (Karlsruhe, D)
sodium dodecyl sulfate (SDS) Roth (Karlsruhe, D)
Tetramethylethylenediamine (TEMED) Roth (Karlsruhe, D)
Tris(hydroxymethyl)aminomethane (Tris) Roth (Karlsruhe, D)
Tris-hydrochloride (Tris-HCl) Roth (Karlsruhe, D)
Polysorbate 20 (Tween 20) Roth (Karlsruhe, D)
WB substrate reagent A, B BD Biosciences (San Diego, CA, USA)
Cell lysis
Beta-glycerophosphate Sigma-Aldrich (Steinheim, D)
Glycerol Roth (Karlsruhe, D)
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Sodium orthovanadate Sigma-Aldrich (Steinheim, D)
Nonidet P-40 (NP40) Fluka Biochemika (Buchs, CH)
Protease inhibitor cocktail Sigma-Aldrich (Steinheim, D)
Phenylmethylsulfonyl fluoride (PMSF) Fluka Biochemika (Buchs, CH)
ELISA
Bovine serum albumine (BSA) Roth (Karlsruhe, D)
Phosphate-buffered saline (PBS) PAA (Linz, A)
Substrate reagent BD Biosciences (San Diego, CA, USA)
Luciferase assay
Passive lysis buffer Promega (Mannheim, D)
Luciferin Biosynth (Staad, CH)
Tricine Sigma-Aldrich (Steinheim, D)
Magnesium sulfate (MgSO4) Sigma-Aldrich (Steinheim, D)
Sodium hydroxide (NaOH) Roth (Karlsruhe, D)
Magnesium carbonate hydroxide
((MgCO3)4Mg(OH)2.5H2O) Sigma-Aldrich (Steinheim, D)
Dithiothreitol (DTT) Roth (Karlsruhe, D)
Adenosine triphosphate (ATP) Sigma-Aldrich (Steinheim, D)
Acetyl coenzyme A Sigma-Aldrich (Steinheim, D)
Table 2.4: Reagents for Cell Biology Methods
Reagents Vendor
Cell culture
Aqua ad iniectabilia Braun (Melsungen, D),
Dulbecco’s modified eagle medium (DMEM) Sigma-Aldrich (Steinheim, D)
fetal bovine serum (FBS) GibcoBRL (Paisley, GB)
L-Glutamine PAA (Linz, A)
OptiMEM R© Invitrogen (Carlsbad, CA, USA)
Penicillin PAA (Linz, A)
Phosphate-buffered saline (PBS) PAA (Linz, A)
Streptomycin PAA (Linz, A)
Trypan blue Sigma-Aldrich (Steinheim, D)
Cryoconservation
Dimethyl sulfoxide (DMSO) Roth (Karlsruhe, D)
Isopropanol Roth (Karlsruhe, D)
Mr. Frosty R© freezing container Thermo Fisher (Waltham, MA, USA)
Viability assay
CellTiter-Blue R© cell viability assay Promega (Madison, WI, USA)
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Transfection
GeneJuice R© transfection reagent EMD chemicals (San Diego, CA, USA)
Lipofectamine RNAiMax R© Invitrogen (Carlsbad, CA, USA)
Poly(I:C) Amersham/GE Healthcare
Flow cytometric cell cycle analysis
Methanol Merck (Darmstadt, D)
Propidium iodide (PI) Sigma-Aldrich (Steinheim, D)
Ribonuclease A Sigma-Aldrich (Steinheim, D)
Plaque assay
LE agarose Biozym Scientific (Hessisch Oldendorf, D)
Crystal violet Sigma-Aldrich (Steinheim, D)
Formaldehyde Roth (Karlsruhe, D)
Ethanol Roth (Karlsruhe, D)
Immunofluorescence microscopy
Crif1 antibody M-222 Santa Cruz Biotechnology (Santa Cruz, CA, USA)
Alexa Fluor R© 488 chicken anti-rabbit IgG Invitrogen (Carlsbad, CA, USA)
DAPI Sigma-Aldrich (Steinheim, D)
HardSet mounting medium Vector Laboratories (Burlingame, CA, USA)
Hoechst 33342 nucleic acid stain Invitrogen (Carlsbad, CA, USA)
MitoTracker R© Green FM Invitrogen (Carlsbad, CA, USA)
MitoTracker R© Red CMXRos Invitrogen (Carlsbad, CA, USA)
Table 2.5: Assays and Kits
Assay Vendor
ELISA Substrate Solution BD Biosciences (San Diego, CA, USA)
GeneJet Plasmid Miniprep Kit Thermo Fisher (Waltham, MA, USA)
JETQuick Spin Columns GENOMED (Lo¨hne, D)
Human IP-10 ELISA BD Biosciences (San Diego, CA, USA)
Human IL-6 ELISA BD Biosciences (San Diego, CA, USA)
Luciferase Assay Kit BioThema (Handen, S)
MEGAscript T7 Kit Ambion (Kassel, D)
PeqGOLD total RNA kit PEQLAB (Erlangen, D)
Plasmid Maxi Kit QIAGEN (Hilden, D)
RNeasy mini RNA extraction kit QIAGEN (Hilden, D)
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2.1.2 Media, Solutions and Buffers
Cell lines were cultured in DMEM medium containing 100IU/mL penicillin, 100µg/mL
streptomycin, 1.5mM L-glutamine and 10% FBS.
DH5α (Invitrogen) were cultured in LB broth or on LB agar, with 100µg/mL ampicillin
or 50µg/mL kanamycin if required for selection.
Other solutions or buffers are listed in table 2.6.
Table 2.6: Solutions and Buffers
Running Buffer Wet transfer Buffer TBE Buffer
192mM glycin 192mM glycin 89mM tris
25mM tris-base 25mM tris-base 89mM boric acid
0.1% SDS 20% methanol 2mM EDTA
in aqua dest. in aqua dest. pH 8.3 in aqua dest.
Lysis Buffer PBSTween Blocking Buffer
20mM tris-HCl (pH 7.5) 0.1% Tween 20 5% milk powder
150mM NaCl in PBS in PBSTween
1.5mM MgCl2
10% glycerol Hybridization Buffer Crystal Violet Solution
0.2% NP40 10mM tris-base 0.5% crystal violet
0.5mM EDTA 1mM EDTA 0.8% NaCl
20MM beta-glycerophosphate pH 7.4 in aqua dest 0.5% formaldehyde
1mM sodium orthovanadate 50% ethanol in aqua dest.
1mM PMSF
10g/L Protease Inhibitor
Cocktail
tris-buffered saline (TBS) TFB1 TFB2
50 mM Tris-Cl, pH 7.5 30mM KAc 10mM MOPS/NaOH (pH 7)
150 mM NaCl 50mM MnCl2 75mM CaCl2
in aqua dest. 100mM RbCl 10mM RbCl
10mM CaCl2 15% glycerol
15% glycerol in aqua dest.
in aqua dest.
to pH 5.8 with HAc
2.1.3 Cells and Viruses
The human embryonic kidney cell line Hek293 was acquired from the American type culture
collection (ATCC).
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The human melanoma cell line 1205Lu was obtained from M. Herlyn (Wistar Institute,
Philadelphia, PA, USA).
Baby hamster kidney fibroblast cell line BHK-21 was kindly provided by Prof. Conzelmann
(Max von Pettenkofer Institute (MPI), Munich, D)
TLR7- and TLR9- cells used for luciferase assays are HEK293 cell lines stably overexpress-
ing TLR-7 or -9, respectively, as well as an NF-κB-controlled firefly luciferase reporter
gene. Both stable cell lines were kindly provided by Prof. Simon Rothenfusser, Ludwig-
Maximilians-Universita¨t (LMU), Germany.
Wildtype VSV Indiana strain expressing green fluorescent protein (GFP) [68] and IFN-
inducing VSV mutant M51R (VSV M) [69] expressing GFP were kindly provided by Dr.
Oliver Ebert from Technical University Munich (TUM), Germany.
Modified vaccinia Ankara (MVA) GFP virus [70] was kindly provided by Dr. Gerd Sutter,
TUM, Germany.
Sendai virus (SeV) Cantell strain was purchased from Charles River Laboratories (Wilm-
ington, MA, USA).
2.1.4 Oligonucleotides
So-called small interfering RNAs (siRNAs) are short double-stranded RNA molecules that
interfere with the expression of specific genes with a complementary sequence. Synthetical
siRNAs are used to induce RNA interference (RNAi) — the knockdown of almost any
protein when transfected to the cytoplasm of mammalian cells. siRNAs used in this study
were obtained from Eurofins MWG (Ebersberg, D). Table 2.7 lists their sequences and
target proteins. If not stated otherwise, siRNAs were designed using the Dharmacon
siRNA center (now Thermo Fisher).
In addition, polymerase chain reaction (PCR) primers used to clone protein inserts from
one expression vector to another are listed in table 2.8. FA primers were designed to
produce a recognition site for the restriction enzymes FseI at the 5’ end and AscI at the 3’
end so that the insert could be easily transferred to vectors containing these two restriction
sites while M primers are primers for site-directed mutagenesis (also see plasmids listed in
table 2.10).
In order to quantify RNA levels of a gene of interest in a cell population relative to a
housekeeping gene, quantitative real time reverse transcription PCR (qRT-PCR) was used.
Primers were designed using the Roche Universal Probe Library system. Table 2.9 sum-
marizes their targets and sequences.
2.1.5 Plasmids
All plasmids used are listed in table 2.10.
Empty pCS2 and pcDNA5 vectors were kindly provided by Prof. Olaf Stemmann, De-
partment of Genetics, University of Bayreuth, Germany. pEGFP-CRIF1-C3 was obtained
from Dr. Martin Mu¨ller from the German Cancer Research Center, Heidelberg, Germany
[77]. pOTB7-RBM10 was purchased from imaGenes (Berlin, D).
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Table 2.7: siRNAs
SiRNA Target Sequence 5’-3’ Reference
CO4 none GCG CUA UCC AGC UUA CGU A [71]
siLamin A Human Lamin A AAC UGG ACU UCC AGA AGA ACA [72]
siMRE11 Human MRE11 UGG CUA AUG ACU CUG AUG AUA
siGL2 Luciferase GL2 CGU ACG CGG AAU ACU UCG A [73]
siRIG-I Human RIG-I 3’UTR CCU UAA CAA UCU ACU GAA A [74]
siRIG-I Human RIG-I AUC ACG GAU UAG CGA CAA A [71]
siMAVS Human MAVS CCA CCU UGA UGC CUG UGA A [75]
siMDA5 Human MDA5 GUA UCG UGU UAU UGG AUU A [75]
siCRIF1 Human CRIF1 GCA GAG UGC AUG GCC AAG A
siCRIF1-2 Human CRIF1 CCA CAG AUG AUU GUG AAC U
siCRIF1-3 Human CRIF1 3’UTR CUU UGU CCC UUC CCA AUA A
siRBM10 Human RBM10 GCC AGU CGU AUA CCA UCA U
siRBM10-2 Human RBM10 CCU GGC AUC UAC CAA CAA U
siIFNAR 0534 Human IFNα receptor UCC UCC AGA AGU ACA UUU A [74]
siIRF3 Human IRF3 AAA UCU ACG AGU UUG UGA A
siSTAT3 Human STAT3 GGG ACC UGG UGU GAA UUA U
siCKII Human CKII GAU CCA CGU UUC AAU GAU A [76]
siGADD45γ Human GADD45γ CAG CCA AAG UCU UGA ACG U
The sequence depicted is the 19-nt portion in the sense strand of the targeted mRNA. 3’ overhangs were
dTdT.
Table 2.8: PCR Primers
Primer Target Sequence 5’-3’
FA211 Human RBM10 variant 1 forward attaGGCCGGCCaATGGAGTATGAAAGACGTGG
FA212 Human RBM10 variant 1 reverse attaGGCGCGCCaCTGGGCCTCGTTGAAGC
FA213 Human CRIF1 forward attaGGCCGGCCaATGGCGGCGTCCGTGC
FA214 Human CRIF1 reverse attaGGCGCGCCaGGAGCTGGGTGCCCCA
Cl281 Human δ MTS CRIF1 forward attaGGCCGGCCaatgGGACCCCGGTGGCCAG
M284 Human CRIF1 mutation R26A forward GGCCCCGGGTTCCCGTGGCTACgcGGCGCGGCCGCCCCCGCGC
M285 Human CRIF1 mutation R26A reverse GCGCGGGGGCGGCCGCGCCgcGTAGCCACGGGAACCCGGGGCC
Upper-case letters indicate sequences coding for restriction sites or target annealing. Lower-case letters
mark base pairs added for methodological reasons.
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Table 2.9: qRT-PCR Primers
Primer Target Sequence 5’-3’ Probe #
3 huIFNbeta left Human IFNβ cgacactgttcgtgttgtca 25
4 huIFNbeta right Human IFNβ gaggcacaacaggagagcaa
91 RBM10 left Human RBM10 ccaagcccaagatcaatgag 76
92 RBM10 right Human RBM10 ttctctcggcgtttgaagtt
93 MAVS left Human MAVS tgtctgccagcacagtcc 32
94 MAVS right Human MAVS gagctgctggggtctcct
95 CRIF1 left human CRIF1 ctggccgaagagcagaag 32
96 CRIF1 right Human CRIF1 tcttggccatgcactctg
113 huRIG-I left Human RIG-I tggaccctacctacatcctga 69
114 huRIG-I right Human RIG-I ggcccttgttgtttttctca
119 huSTAT3 left Human STAT3 cccttggattgagagtcaaga 14
120 huSTAT3 right Human STAT3 aagcggctatactgctggtc
129 huCKII left Human CKII gcgccaatatgatgtcagg 74
130 huCKII right Human CKII tggaacaggcatcccaag
Plasmids containing RIG-I, MAVS, MDA5, pTBK1, RIG-I-CARD and pIRF3-5D were
kindly provided by Prof. Katherine Fitzgerald, University of Massachusetts Medical School,
USA. pNEMO was obtained from Prof. Karl-Klaus Conzelmann, MPI, Munich, Germany.
All other plasmids were cloned from the empty vectors and inserts listed above and in table
2.10.
2.2 Methods
2.2.1 Molecular Biology Methods
Molecular biology provides techniques of RNA and DNA preparation and manipulation.
Genes of interest can be cloned and modified by PCR, cut and pasted by enzymatic di-
gestion and ligation, separated by electrophoresis, propagated as plasmids in bacteria, and
inserted into expression vectors. Cells can be stimulated with artificially transcribed nucleic
acids and mRNA expression levels monitored by qRT-PCR. All these tools are essential
to study protein and cellular function.
Expression Cloning
Expression cloning is used to study the function of a protein. DNA coding for the pro-
tein is inserted into a circular expression vector using PCR or restriction enzymes. The
expression vector can then be inserted and expressed, for example in a mammalian cell
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Table 2.10: Plasmids
Plasmid Insert Vector Tag
pcDNA5 none pcDNA5-FRT/TO-FA none
p5-mCherry none pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
p5-GFP none pcDNA5-FRT/TO-FA-GFP C-term. GFP
p5-flag none pcDNA5-3xflag-FRT/TO-FA N-term. flag
pCS2-myc none pCS2-MYC-FA N-term. myc
p5-RIG-I huRIG-I pcDNA5-FRT/TO-FA none
p5-RIG-I-mCherry huRIG-I pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
p5-RIG-I-GFP huRIG-I pcDNA5-FRT/TO-FA-GFP C-term. GFP
p5-RIG-I-flag huRIG-I pcDNA5-3xflag-FRT/TO-FA N-term. flag
p5-MAVS huMAVS pcDNA5-FRT/TO-FA none
p5-MAVS-mCherry huMAVS pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
p5-MAVS-flag huMAVS pcDNA5-3xflag-FRT/TO-FA N-term. flag
p5-MDA5 huMDA5 pcDNA5-FRT/TO-FA none
pEGFP-CRIF1-C3 huCRIF1 pEGFP-C3 N-term. GFP
pCS2-CRIF1-myc huCRIF1 pCS2-MYC-FA N-term. myc
p5-CRIF1 huCRIF1 pcDNA5-FRT/TO-FA none
p5-CRIF1-mCherry huCRIF1 pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
p5-CRIF1-flag huCRIF1 pcDNA5-3xflag-FRT/TO-FA N-term. flag
p5-CRIF1-δMTS-mCherry huCRIF1-δMTS pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
p5-CRIF1-R26A-mCherry huCRIF1 mut R26A pcDNA5-FRT/TO-FA-mCherry C-term. mCherry
pOTB7-RBM10 huRBM10 pOTB7 none
p5-RBM10 huRBM10 pcDNA5-FRT/TO-FA none
p5-RBM10-GFP huRBM10 pcDNA5-FRT/TO-FA-GFP C-term. GFP
pTBK1 huTBK1 pcDNA3-flag flag
pNEMO huNEMO pGCAGGS N-term. flag
RIG-I-CARD huRIG-I-CARD pEF-Bos-flag N-term. flag
pIRF3-5D huIRF3-5D pCMV-flag flag
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line. Restriction enzymes are bacterial enzymes that can degrade foreign, e.g. viral, DNA
by recognizing and cutting specific palindromic sequences. As they do not degrade other
parts of the DNA, a desired sequence can be cut precisely and pasted into a new vector
using the enzyme T4 ligase. An expression vector requires an origin of replication and a
selection gene such as an antibiotic resistance for selective amplification in bacteria, as well
as a multiple cloning site to add a gene of interest. All vectors used here also contain a
promotor for expression of the protein in mammalian cells. Inserts were cloned without
a stop codon so n- or c-terminal tags as contained in the vector would be fused to the
inserted protein when expressed.
To construct the expression vectors used here, the FseI-AscI (FA) system was used. With
a restriction site for FseI at the 5’-end of the insert and AscI at the 3’end, inserts can be
transferred easily into all vectors containing those same restriction sites as indicated by
FA in their name.
Restriction sites for FA cloning of full-length CRIF1 and RBM10 as well as the mitochon-
drial targeting sequence (MTS) deletion mutant δMTS-CRIF1 were introduced via PCR.
RIG-I, MDA5 and MAVS were already available in vectors containing FA restriction sites.
To open restriction sites in the vector and insert for ligation, 1µg DNA was cut using
2U/50µL FseI, 10U/50µL AscI in 50µL in NEBuffer 4 (New England Biolabs) diluted with
ddH2O. The enzyme-DNA-mixture was incubated at 37˚C for one hour before the enzymes
were inactivated by heating them to 65˚C for 20 minutes. To prevent religation of the
vector, it was incubated with 1µL calf intestine alkaline phosphatase (CIAP) for another
hour at room temperature (RT) to remove 5’-phosphate groups. Insert and linearized vector
were each purified using agarose gel electrophoresis. Then the bands of interest were cut
out, dissolved and extracted using JETQuick Spin Columns (GENOMED) according to
the manufacturer’s protocol.
For ligation, 0.5µL of the linearized and purified vector were incubated for one hour at RT
with 16µL insert, 2µL ligase buffer and 1µL T4 ligase. Afterwards, 10µL of the ligation
mixture were transformed into heat-competent DH5α.
After transformation, bacteria were plated on ampicillin selection plates and incubated at
37˚C overnight. Colonies were picked the next day, amplified by culture in LB broth and
plasmids were purified by Plasmid Miniprep (Thermo Fisher) according to the manufac-
turer’s protocol. To ensure the correct insert, rotation and sequence, plasmids were tested
via restriction digestion and sequencing (MWG value read tubes).
Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) is an enzymatic reaction to amplify stretches of DNA
and to modify desired sequences. It requires cycles of heating and cooling during which
double-stranded DNA is melted and replicated with a heat-stable DNA polymerase. Primers
with sequences complementary to the ends of the region of interest initiate the reaction and
can be used to add changes to the sequence, like the addition of restriction sites. As newly
produced DNA also serves as a template in following cycles, exponential amplification of
the desired sequence is achieved.
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PCR was utilized to retrieve inserts from their original vectors and to add the desired
restriction sites for FseI and AscI at at the 5’- and 3’-end, respectively, using the primers
listed in table 2.8.
For the reaction, 100ng of template DNA were mixed with 5µL Pfu buffer Mg2+ (Fermen-
tas), 1µL deoxyribooligonucleotides (dNTPs), 1.25µL 5’- and 3’-primer each (10pmol/µL),
0.5µL Pfu polymerase (Fermentas) and dH2O up to a total of 50µL. In a thermocycler, the
reaction mix was heated to 95˚C for two minutes and then underwent the following cycles
20-35 times: denaturing the double-stranded DNA by heating to 95˚C for 45 seconds,
annealing the primers by cooling down to at least 3˚C below the melting temperature of
each primer for 45 seconds, then elongating the sequence of interest during one minute per
kilobase (kb) at 72˚C. After the last cycle, all sequences were allowed a final extension
time of ten minutes at 72˚C before cooling them down for further processing.
Site-Directed Mutagenesis
Site-directed mutagenesis or Quick-change PCR inserts specific point mutations into a
vector by amplifying the entire vector using primers that are complementary to it except
for the desired mutation.
After amplification, parental DNA is degraded using the enzyme diplococcus pneumoniae
restriction enzyme I (DpnI). DpnI only cleaves methylated DNA, so mutated DNA syn-
thesized in vitro is left intact while parental DNA produced by E.coli is degraded.
The reaction mix was prepared using 5µL of 10x reaction buffer, 50ng of template vector,
1,25µL (125 ng) of each primer, 1 µL of dNTP mix and ddH2O to a final volume of 50µL.
After adding 1 µL of Pfu DNA polymerase (2.5 U/µL), the reaction was started by heating
the mixture to 95˚C for 30 seconds. This was followed by 18 cycles of heating to 95˚C
for 30 seconds to trigger strand separation, then cooling down to 55˚C for one minute
to allow annealing of the primers and heating to 68˚C for one minute per kb of plasmid
length to amplify the target vector.
After amplification, the mixture was cooled down to ≤ 37˚C before 1µL DpnI was added to
degrade the original, non-mutated DNA. The reaction mix was spun down and incubated
at 37˚C for one hour before transformation.
After transformation, bacteria were plated on selection plates and incubated at 37˚C
overnight. Colonies were picked the next day, amplified by culture in LB broth, purified
by miniprep and sequenced (MWG value read tubes) to prove the desired mutation was
present.
Agarose Gel Electrophoresis
Linearized DNA fragments were separated with, and isolated from, agarose gels. By apply-
ing an electric field to DNA in an agarose gel, the negatively charged molecules are pulled
through the matrix and separated by size. DNA is made visible under ultraviolet (UV)
light by adding ethidium bromide, which will fluoresce when intercalated into DNA. DNA
bands made visible by ethidium bromide were cut and purified from the gel.
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1.5% gels were cast using 3g agarose dissolved in 200mL tris-acetate EDTA (TAE) (40mM
Tris acetate and 1mM EDTA) and 20µL ethidium bromide. 50µL of DNA sample was
mixed with 10µL of loading dye and gels were run in TAE at 90V for 30-45 seconds.
Afterwards, bands were visualized on a transilluminator (LKB) and cut out for further use
or photographed for record on an AlphaImager (Alpha Innotech).
To reisolate DNA from bands cut out of agarose gels, JETQuick Spin Columns (GENOMED)
were used according to the manufacturer’s specifications.
Generation of Heat-Competent Bacteria and Transformation
Competence describes a bacterium’s ability to take up extracellular DNA. Bacteria like
DH5α can be made artificially competent by rubidium chloride treatment.
To achieve optimal competence, bacteria must be in exponential growth phase. For this,
they were thawed, incubated overnight in 2mL LB-medium at 37˚C, then incubated in
100mL LB-medium with 2mL 1M potassium chloride (KCl) and 2mL magnesium sulfate
(MgSO4) up to an OD600 of 0.4-0.55. The bacteria were then centrifuged 10’ at 4000rpm,
4˚C, and the supernatant was decanted. They were resuspended in 15mL TFB1 solution
and incubated five minutes on ice. Afterwards, the bacterial suspension was centrifuged
again, the supernatant was decanted, and the bacteria were resuspended in 4mL ice-cold
TFB2. Aliquots of 100µL were frosted in liquid nitrogen and stored at -80˚C.
Transformation, the uptake of extracellular DNA by bacteria, was achieved by incubating
heat-competent bacteria with the plasmid on ice for ten minutes, then subjecting them to
a heat shock of 42˚C for one minute and placing them back on ice.
Quantitative Real Time Reverse Transcription PCR
In order to determine mRNA-expression levels, quantitative real time reverse transcription
PCR (qRT-PCR) can be used.
First, RNA is isolated and transcribed to complementary DNA (cDNA) using the enzyme
reverse transcriptase. In the case of mRNA, which has a poly-A-tail, an oligo-dT-primer
can be used to initiate transcription.
Next, DNA is then detected and quantified simultaneously using real-time polymerase
chain reactions. For this, fluorescently labeled DNA probes are combined with specific
primers to detect a certain cDNA sequence. For this, a DNA probe marked with a fluo-
rophore binds to the DNA sequence in question. A quencher molecule attached to the same
probe hinders it from fluorescing due to its proximity. When the sequence is amplified,
the exonuclease activity of the polymerase degrades the probe and separates fluorophore
and quencher. Without close proximity of the quencher, fluorescence emmission of the
fluorophore can be measured after excitation with UV light. As the target sequence is
amplified exponentially by the polymerase, more and more fluorophores are set free and
an exponential increase in fluorescence can be detected. From this increase, the amount of
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original RNA relative to a constitutively expressed housekeeping gene can be calculated.
For reverse transcription, a volume of 10.5µL RNA (about 1µg) purified from cultured cells
with an RNA extraction kit was annealed with 2µL oligo-dT-primer (10pmol/µL) at 70˚C
for five minutes. 1µL reverse transcriptase, 4µL 5x reaction buffer, 2µL dNTPs (10mM
ATP, CTP, GTP, and TTP in equal volumes), and 0.5µL RNAse inhibitor were added
and the mixture was incubated at 37˚C for one hour before the enzyme was inactivated
by heating it to 70˚C for ten minutes. The resulting cDNA mixture was diluted in 30µL
H2O. From this DNA mixture, 6µL were used per measurement together with 10µL 2x
buffer (LightCycler 480 Probes Master), 0.4µL of each primer (10pM/µL), 0.2µL of a
fluorescent probe from Roche Universal Probe Library and another 3µL of sterile water.
Assays were designed using the Roche ProbeFinder Assay Design Software. The amount
of target gene expression in the cDNA mixture was determined as copy numbers per copy
of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT).
In-Vitro Transcription
5’-triphosphate RNA was transcribed in vitro using T7 phage polymerase and the MEGAscript
T7 Kit from Ambion.
First, transcription templates were generated from DNA oligonucleotide templates con-
taining the 2.2s sequence TCAAACAGAGGTCGCATGCCTATAGTGAGTCGTA and a
sequence complementary to the Ambion T7 promotor primer sequence TAATACGACT-
CACTATA at its 3’ end. For this, 2µL DNA template 2.2s (100pmol/mL) was incubated
with 2µL primer of the same concentration in 10µL DNA hybridization buffer. Double-
stranded DNA was denatured at 70˚C and cooled down two hours to 4˚C. Incomplete
3’ ends were filled with ExoKlenow R© polymerase by adding 5µL RNAse-free water, 2µL
ExoKlenow R© buffer, 2µL dNTPs (2.5mM) and 2µL of the enzyme to the reaction mix and
incubating at 37˚C for 30 minutes. Afterwards, the enzymes were denatured 5 minutes at
70˚C.
For the final in vitro transcription, the MEGAscript T7 Kit (Ambion) was used according to
the manufacturer’s specifications. RNA was extracted using phenol–chloroform extraction
and measured photometrically by determining the absorption at 260nm.
The final sequence of 2.2s 5’-triphosphate RNA was GGCAUGCGACCUCUGUUUGA
[78].
For stimulation, 5’-triphosphate 2.2 single-stranded RNA was annealed with 2.2 antisense
OH-RNA to form double-stranded RNA.
2.2.2 Cell Biology Methods
Cell Culture
Cells were cultured at 37˚C, 5% CO2 and 95% humidity. Every two to four days, they
were split using 0.05% trypsin and medium was refreshed.
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When not in use, cells were cryoconserved in FBS with 10% DMSO by reducing their
temperature at 1K/minute in an isopropanol freezing container and storing them at -80˚C.
Celltiter-Blue Viability Assay
The resazurin-based viability assay can be used to measure cell proliferation and viability.
Resazurin is a blue redox dye that viable cells turn into a pink, fluorescent dye called
resorufin. To measure cell viability with this assay, 20µL of the reagent are put into 500µL
medium per well on a 24-well-plate and incubated for 20 to 30 minutes until there is a
change in color. Fluorescence is measured with an excitation wavelength of 530 and an
emission wavelength of 590nm with a Mithras Multiplate Reader.
SiRNA-Knockdown
For siRNA-knockdown in 1205Lu melanoma cells, 3x104 cells/well were plated in 0.5mL
medium on a 24-well-plate and incubated overnight. The next day, 1µL 20µM siRNA and
0.9µL Lipofectamine
TM
RNAiMAX Transfection Reagent reagent were mixed with 50µL
OptiMEM serum-free medium each and incubated at RT for five minutes. Then, the two
reagents were combined and incubated at RT for 15 minutes. The mixture was added in
small drops to the cells, which were then incubated at 37˚C for 24 hours. The procedure
was repeated after 24 or 48 hours.
For experiments, where 96-well-plates were used, the volumes were scaled down to 0.2µL
Lipofectamine
TM
RNAiMAX and 0.2µL siRNA diluted in 25µL OptiMEM each, following
the protocol described above.
For experiments in 6-well-plates, the volumes were scaled up to 5x105 cells in 3mL medium
treated with 5µL Lipofectamine
TM
RNAiMAX and 5µL siRNA diluted in 150µL OptiMEM.
siRNAs were designed using the online siDESIGN center (Dharmacon). All sequences
were blasted against the National Center for Biotechnology Information (NCBI) human
transcript database to avoid off-target effects.
Cell Stimulation with 5’-Triphosphate-RNA
5x103 cells/well were plated in 100µL DMEM into a 96-well-plate and stimulated with
triphosphate RNA 24 hours after transfection of siRNA. For this, 0.2µL Lipofectamine
TM
RNAiMax and 200ng triphosphate-RNA were mixed with 25µL OptiMEM serum-free
medium each and incubated for five minutes at RT. After combining the two ingredi-
ents and incubating them together for 15 minutes, the mixture was added to the cells one
drop at a time. These were then incubated overnight, before cytokines were measured in
the supernatant.
Plasmid Expression
3x104 cells were plated in one compartment of a 35mm 4-compartment cell culture dish
with 500µL medium and incubated overnight. For transfection, 0.75µL GeneJuice Trans-
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fection Reagent (EMD chemicals) were diluted in 20µL OptiMEM serum-free medium and
incubated for five minutes, then mixed with 250ng plasmid and incubated for another five
to fifteen minutes. The mixture was added to the cells one drop at a time and incubated
at 37˚C for 48 hours.
Flow Cytometry
Flow cytometry is a sensitive technique to detect different properties of cells or microscopic
particles. A beam of laser light of a single wavelength is shot at a passing cell in a
stream of fluid. Different light detectors analyze different characteristics of the passing
cells: the forward scatter (FSC) contains information about the volume, the side scatter
(SSC) contains information about the inner complexity of the cells. If the cell contains
a fluorophore like GFP, light emitted from the excited molecule can be detected with a
fluorescence detector.
Flow Cytometric Infection Assay
Using a mutant VSV that expresses free GFP within mammalian cells, it is possible to
distinguish between infected and uninfected cells and to analyze infection rates in different
populations. This technique was combined with siRNA knockdown experiments to obtain
quantitative infection analyses.
For infection analyses, 3x104 1205Lu cells were plated in a 24-well-plate, then incubated
overnight, and knockdowns were performed twice with a 24-hour incubation interval. Cells
were then infected with a multiplicity of infection (MOI) of 0.1 of VSV M GFP in serum-
free medium. The medium was changed to normal growth medium after one hour. Ten
hours post infection, cells were harvested and analyzed.
Cell Cycle Analysis
Flow cytometry can be used to distinguish cells at different stages of the cell cycle. Cellular
DNA is quantitatively stained with the fluorescent marker PI. As cells double their DNA
content during S-phase, the relative amount of cells in G0/G1 (before S-phase) or G2/M-
phase (after S-phase) can be determined by measuring the fluorescence signal.
To analyze changes in cell cycle, 1205lu cells/well were plated into a six-well-plate and
incubated overnight. Knockdowns were performed according to the experimental protocol
described above. After the second knockdown, cells were trypsinized, washed with phos-
phate buffered saline (PBS), pelleted and fixated as well as permeabilized by resuspending
them in 0.5mL 70% methanol and incubating them for one hour at RT. After two addi-
tional washes in PBS, the cells were resuspended in 250µL PBS. RNA that could interfere
with the DNA stain was degraded by adding 1µL ribonuclease A (stock: 1mg/mL in aqua
dest.) and incubating 20 to 30 minutes at 37˚C. 5µL PI (stock: 1mg/mL in aqua dest.)
were added and the solution was incubated on ice for at least 20 minutes.
PI fluorescence was measured on the FL3 channel on a FACSCalibur cytometer.
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Plaque Assay
A plaque assay was used to measure the concentration of a cytolytic virus like VSV by
infecting cells with different dilutions of the original virus solution and counting the cell-free
spots called plaques that form on a cell layer.
Specifically, a layer of cells susceptible to the virus in question is grown to confluency and
infected with a serial dilution of the virus. The virus has to be hindered from moving freely
through the medium so newly produced virus will not infect all cells in the well. For this,
cells are covered with an agarose lid. Underneath, the virus can only infect neighboring
cells, so one infectious particle in the original solution will produce exactly one plaque.
After a virus-specific incubation period, the agarose lid is removed and the cell layer is
stained with crystal violet. After washing, plaques become visible and can be counted to
calculate the original virus concentration.
To determine the concentration of VSV in the supernatant after an infection experiment,
106 BHK-21 cells were plated per well of a six-well-plate and grown to confluency. The viral
supernatants were diluted ranging from 1:103 to 1:108 and the cells were infected for one
hour in serum-free medium. To cover the cells, 1% agarose was dissolved in heated PBS,
mixed with the same volume of medium, and allowed to cool down to less than 40˚C so
as to not harm the cells. Each well was covered with 2mL of the agarose solution. After a
few minutes at RT, the agarose lid was hardened and the cells were incubated for 24 hours
at 37˚C. Next, the lid was removed and the cells stained with a few drops of crystal violet
solution for three minutes before washing with tap water until plaques became visible.
From the counted plaques in the wells of the dilution series, the original concentration was
calculated as plaque forming unit (PFU)/mL.
Immunofluorescence Microscopy
In order to visualize and determine its intracellular localization, the target protein was
either fused to a red or green fluorescent protein and overexpressed or marked with a
fluorescently labeled antibody before being visualized with a confocal microscope.
For localization of tagged protein in living cells, 5x104 1205Lu cells were plated into one
compartment of a 35mm 4-compartment glass bottom dish. After one night of incuba-
tion, 250ng of plasmid were transfected into the cells with GeneJuice Transfection Reagent
(EMD chemicals) according to the manufacturer’s protocol and the transfected cells were
incubated for two days. Next, 20nM MitoTracker R© Green FM and 0,2µg/mL Hoechst
33342 nucleic acid stain (both Invitrogen) were added to the culture medium to stain mi-
tochondria and nuclei, respectively. After another 30 minutes of incubation, the cells were
viewed with a confocal microscope.
To localize native protein in fixated cells, 5x104 1205Lu cells were plated on a round
12mm microscope cover slip. The prepared slip was put into one well of a 24-well-plate
and incubated until the cells were 70-90% confluent. 30 minutes before fixation, the cells
were stained with 100nM MitoTracker R© Red CMXRos (Invitrogen). The medium was
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removed and the cells were fixated in 100% methanol at -20˚C for ten minutes. After
one hour of blocking in 10% FCS in PBS, they were stained with primary anti-CRIF1-
antibody M-222 (Santa Cruz Biotechnology) for one hour at RT, rinsed twice with PBS, and
stained for another hour with Alexa Fluor 488 R© chicken anti-rabbit antibody (Invitrogen),
a green fluorescent secondary antibody. Next, they were rinsed twice with PBS again,
stained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich), a nuclear stain with
a blue (461nm) emission, rinsed again and mounted on a microscope slide with hardset
fluorescence mounting medium.
2.2.3 Biochemical Methods
SDS-PAGE and Western Blot
SDS-polyacrylamide gel electrophoresis (PAGE) separates proteins in an electric field ac-
cording to their respective size and charge.
SDS, an anionic detergent, denatures proteins in the sample, linearizes them and provides
them with a negative charge. The gel is made up of acrylamide and bisacrylamide poly-
merized by added ammonium persulfate and TEMED. It functions as a sieve that allows
smaller proteins to pass quickly through the electric field while holding back larger pro-
teins. However, the natural charge of a protein also influences its movement through the
gel, hence the separation is not only dependent on size. The gel can be blotted onto a
membrane to stain single proteins with a specific antibody. This process is called western
blot.
For the experiments described here, 20µL laemmli buffer were mixed with 20µL protein
lysate and heated to 95˚C for five minutes. For a 15% acrylamide gel, 2.4mL H2O were
mixed with 2.5mL 1.5M Tris-HCl, pH 8.8, with 10%SDS, 5mL Rotiphorese R© Gel 30 acry-
lamide/bisacrylamide solution, 0.1mL APS (10%) and 0.004mL TEMED. A stacking gel
of 4% was mixed using 2.26mL H2O with 1mL 0.5M Tris-HCl, pH 6.8, with 10% SDS,
0.68mL acrylamide/bisacrylamide, 0.04mL APS and 0.004mL TEMED.
Protein marker and samples were filled into individual slots and the gel was run at 40mA
in running buffer (Table 2.6) until sufficient separation of the marker bands was visible.
Next, the gels were blotted onto a PVDF transfer membrane for 50 minutes at 360mA
using a wet transfer system. To eliminate unspecific binding sites, the blot was blocked in
blocking buffer for 30 minutes. After washing in TBST (TBS with 0.1% Tween 20), the blot
was incubated for two hours with primary antibody diluted in 2% BSA in PBS according
to the manufacturer’s instructions. Unbound antibody was washed off with TBST before
incubating the blot with the secondary, horseradish peroxidase (HRP)-conjugated antibody
diluted 1:3000 in blocking buffer for another two hours. After another washing step, the
blot was developed by mixing 500µL each of substrate reagent A and B (BD Biosciences)
and adding the mixture to the membrane before taking chemiluminescence pictures with
an AlphaImager HP (Alpha Innotech).
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Enzyme Linked Immunosorbent Assay (ELISA) for IP-10 or IL-6
The levels of the cytokines interferon gamma induced protein 10 kDa (IP-10) and IL-6
in the supernatant of cells were detected using a sandwich enzyme linked immunosorbent
assay (ELISA). This method uses antibodies to bind the substance to be measured and
detect it by catalyzing a reaction that creates a measurable absorbance shift.
The coating antibody is bound to the surface of a plastic plate with a basic coating buffer,
then the sample is added and the cytokine can bind to the antibody. In addition, a
detecting antibody binds to a second epitope of the substance and is then bound by a
secondary antibody. The secondary antibody is directed against the constant region of
the detection antibody and carries the enzyme HRP. Superfluous sample or antibody is
washed off after each step. Therefore, the substrate turnover is relative to the cytokine
amount in the sample when a substrate for the enzyme is added.
To retrieve the supernatants with the secreted cytokines, 1205Lu melanoma cells were
plated on a 24- or 96-well-plate and incubated at 37˚C. Transfection with siRNA was
performed after 24 and 72 hours, respectively. 10 to 20 hours after the second siRNA
transfection, cells were infected with VSV (MOI=3), 40U/mL SeV or stimulated with
200ng/well of triphosphate RNA. After 24 hours of stimulation, the plates were centrifuged
at 400g for five minutes and 100-200 µL supernatants were acquired. The supernatants
were diluted 1:2 or 1:4 in PBS to achieve concentrations within the test’s range.
The assay was performed according to the manufacturer’s specifications (BD Biosciences).
Each time, an internal standard was included for all plates so that the absolute amount of
IP-10 or IL-6 could be calculated from the measured absorbance at 450nm.
Protein Complex Immunoprecipitation (Co-IP)
Immunoprecipitation is a method to isolate a protein from a mixture or cell lysate using a
specific antibody. For this procedure, the antibodies are bound to agarose beads that can
be separated from the mixture via centrifugation. If the target protein is part of a larger
complex, immunoprecipitation can be used to pull down interacting proteins together with
the protein targeted by the antibody. Using this method, new interacting partners can be
identified and verified.
For Co-IP, 2.5x104 HEK293 cells were plated in a 10cm dish and incubated overnight. Next,
the cells were transfected with flag-tagged RIG-I plasmid or an empty control plasmid
and either RBM10-GFP or CRIF1-myc plasmid, adding up to a total of 3µg DNA per
dish. After another 24 hours of incubation, cells were infected with 0,1 MOI of VSV M in
OptiMEM for one hour, then rinsed with PBS and incubated in full growth medium for
another 16 hours. The infected cells were then washed in ice-cold PBS three times before
being lysed in 400µL lysis buffer containing 0.2% NP40, 20mM Tris-HCl (pH 7.5), 150mM
NaCl, 1.5mM MgCl2, 10% Glycerol, and 0.5mM EDTA. 20mM beta-glycerophosphate,
1mM sodium orthovanadate, 1mM PMSF, and 10µg/µL LPC were added to the lysis
buffer directly before use. For disruption of the cell membranes, cells were drawn into a
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syringe five times. Membranes and cell detritus were pelleted by 30 minutes centrifugation
at 4˚C and 10,000g and discarded, the supernatant was then incubated with 50µL anti-flag
agarose beads for one hour. Afterwards, the bead-lysate mixture was centrifuged for one
minute at 4˚C and 1000rpm and washed in lysis buffer three times before being loaded onto
a Micro-BioSpin Chromatography Column and centrifuged again one minute at 1000rpm.
To elute the proteins from the beads, the column was incubated with 30µL 3xflag-peptide
(100µg/mL) in TBS for 15 minutes and then centrifuged three minutes at 1000rpm. Both
the eluate and samples from centrifuged cell lysate and bead supernatant were analyzed
by SDS-PAGE and western blot.
Luciferase Reporter Assay
Luciferase is an enzyme that can produce light by the oxidation of a luciferin. If it is
expressed in a cell line under the control of a specific promotor, it can be used to quantify
transcriptional activity.
For this study, stable HEK293 cell lines expressing a firefly luciferase under the control of
an NF-κB dependent promotor were used. Additionally, one of the cell lines overexpressed
TLR-7, the other TLR-9.
5x103 cells/well were plated in 100µL DMEM in a 96-well format and incubated overnight
before they were stimulated with R848 for TLR-7 activation or untransfected cytosine
phosphodiester guanine oligodeoxynucleotides (CpG ODNs) for TLR-9 activation. After
24 hours of stimulation, the supernatant was removed and cells were lysed with 50µL
Passive Lysis Buffer (Promega) for 20 minutes at RT. A substrate stock was prepared
from 20mM Tricine, 2.67mM MgSO4.7H2O, 0.1mM EDTA pH8, 33.3mM DTT, 0.53mM
ATP, 270µM Acetyl CoA, 5mM NaOH, 30mg luciferin, 0.265mM magnesium carbonate
hydroxide and water to a final volume of 228ml. The substrate stock was aliquoted and
stored at -20˚C. Of this stock, 20µL/well were placed in a luminescence reader plate and
mixed with 20µL cell lysate. Luminescence was measured with a Mithras multiplate reader.
2.2.4 Statistical Analysis
For statistical analysis and graphs, GraphPad Prism 5 (GraphPad Inc.) was used. Two-
tailed Student’s t test was used to assess the significance of mean differences. Differences
were deemed significant at a p ≤ 0.05. Statistical significance is indicated by ns for p ≥
0.05, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. Data are shown as means ± standard error
of means (SEM).
Chapter 3
Results
3.1 Depletion of CRIF1 Facilitates Viral Replication
The proteins CRIF1 and RBM10 were found by mass spectrometry to co-precipitate with
RIG-I-FLAG in VSV-infected HEK293 cells. Neither of them have been previously reported
in the literature to have a function in anti-viral immunity. However, some very preliminary
experiments in our group had indicated they might play a role in RLH signaling.
Therefore, in order to further test the hypothesis that CRIF1 and RBM10 play a role in
RIG-I-mediated antiviral immunity, loss-of-function experiments were performed in a hu-
man cell line using RNA interference to knock down the expression of CRIF1 and RBM10.
As an infection model, genetically modified VSV mutants that express GFP within infected
cells were chosen. Infected cells are then easily identified by the expression of GFP and
can be visualized by fluorescence microscopy or measured by flow cytometry.
VSV is an arthropod-born virus with a broad tissue tropism that is recognized by RIG-I.
Its negative, single-stranded RNA genome encodes five proteins. Among them, the multi-
functional matrix protein can disrupt cellular mRNA transcription and export from the
nucleus [79]. Thus, the expression of anti-viral genes like IFN type I is inhibited. As
wildtype (wt) VSV only induces small amounts of IFN-β in 1205lu cells, a well-described
mutant strain was included in order to study IFN dependent anti-viral activity. This mu-
tant strain had lost its ability to inhibit IFN production through a methionine to arginine
mutation at position 51 of the matrix protein (M51R) [80].
As our cell culture model we used the human melanoma line 1205Lu that had been shown
previously to have an intact RLH signaling pathway and had worked well in siRNA-
mediated knockdown protocols before [71].
After optimization of infection time and MOI, we were able to establish an infection model
using an MOI of 0.5 for the wildtype VSV and 5 MOI for the mutant VSV M that gave
us similar intermediate infection rates after 8 hours in 1205Lu cells. Cells in this model
responded well to external IFN type I with a decreased percentage of infected cells and
reacted to inhibition of IFN-signaling with an increased percentage of infected cells. As
VSV M induces more IFN type I, this virus is more susceptible to inhibition of IFN sig-
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naling, while both viruses react equally to externally added IFN type I (see figure 3.1).
Figure 3.1: Infection Rates of 1205Lu Cells by VSV wt and VSV M51R are Sensitive to Both
External Added IFN Type I and Blockade of IFN Receptor Signaling
A: 1205Lu cells were treated with IFN-β (2000U/ml) 30 minutes before or after infection with VSV GFP
wt (MOI=0.5) or VSV GFP M51R (MOI=5). 8h later, the percentage of GFP-positive (=infected) cells
was determined by flow cytometry. Data are shown as mean + SEM of n=3. B: 1205Lu cells were
depleted of the IFN-α receptor using RNA interference. 48h after the first treatment with siRNA, the
cells were infected with VSV GFP wt (MOI=0.5) or VSV GFP M51R (MOI=5). 8h later, the percentage
of GFP-positive (=infected) cells was determined by flow cytometry. *p ≤ 0.05 indicates significance
levels comparing cells treated with siRNA against IFNAR with cells treated with control siRNA.
This infection model was then used for loss-of-function assays depleting CRIF1 and RBM10
by siRNA.
An siRNA called CO4 without a mammalian target was used to control for unspecific ef-
fects. As positive controls, siRNAs targeting RIG-I or MAVS were used, as these molecules
are both known to mediate innate immune responses to VSV.
Knockdown efficiencies were higher than 80% for all used siRNAs (see figure 3.3 and data
not shown). As seen in figure 3.2, depletion of CRIF1 leads to a significantly increased
number of VSV-infected cells. This effect is as strong as or even stronger than knocking
down the known antiviral proteins RIG-I or MAVS. In addition, measuring the virus titer
via plaque-assay in the supernatant of VSV-infected cells depleted of CRIF1 also showed
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an increase in virus titer, confirming the notion that loss of CRIF1 leads to an advantage
for the virus. Loss of RBM10, in contrast to CRIF1, showed no consistently significant
effect on the number of virus-infected cells or the virus titer in the supernatant.
Figure 3.2: Depletion of CRIF1 Facilitates Viral Replication
1205Lu cells were depleted of the indicated proteins using RNA interference. Cells were treated twice
(24h apart) with siRNA or the non-targeting control CO4. 48h after the first treatment, cells were
infected with VSV GFP wt (MOI=0.5) or VSV GFP M51R (MOI=5). 12h later, the percentage of
GFP-positive (=infected) cells was determined by microscopy or flow cytometry and the titer of infective
particles was determined in the supernatant by plaque assays. A: Representative microscopic pictures
of one experiment are shown. B: The percentage of GFP-positive cells was microscopically counted
in 4 representative visual fields and is given as means + SEM of n=4 independent experiments. C:
The percentage of GFP-positive cells was determined by flow cytometry and is given as means + SEM
of n=5. D: The titer of infective VSV particles was determined in the supernatant by plaque assays.
One representative experiment out of three is shown. *p ≤ 0.05, **p ≤ 0.01.,***p ≤ 0.001 indicate
significance levels comparing CO4-treated cells and cells treated with targeting siRNAs.
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3.2 Depletion of CRIF1 or RBM10 Leads to Reduced
Cytokine Production after Infection with RNA
Viruses or Stimulation with RLH Ligands
Depletion of CRIF1 was found to increase the viral replication rate by a mechanism that
was left to be explained. As seen in Figure 3.1, the replication assay used is very sensitive
to changes in interferon signaling. We therefore investigated if knockdown of CRIF1 or
RBM10 influences the induction of interferon or the production of interferon-inducible
genes. To that end the transcription of IFN-β and production of interferon gamma induced
protein 10 kDa IP-10 were measured in cells stimulated with the known RIG-I-triggering
stimuli triphosphate RNA, VSV or SeV (Figure 3.3)
While 1205lu cells did not produce detectable levels of IP-10 without a stimulus (not
shown), RIG-I stimulation resulted in the secretion of 100-400pg/mL IP-10 in the super-
natants of wild-type cells (not shown) or cells treated with a non-targeting control siRNA
(Figure 3.3 A). Interestingly, depletion of both CRIF1 and RBM10 via siRNAs effectively
diminished IP-10 induction and IFN-β production induced by stimulants of RIG-I signaling
to a similar extent as the siRNA-mediated depletion of RIG-I and MAVS used as positive
controls (figure 3.3). These results suggest depletion of CRIF1 or RBM10 impairs signaling
via the RIG-I-IFN pathway.
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Figure 3.3: Depletion of CRIF1 or RBM10 leads to reduced IP-10 and IFN-β production in
response to RIG-I stimulation
5x103 1205lu melanoma cells per well were plated on a 96-well plate and treated twice, 24h apart, with
the indicated siRNAs. 48h after the first treatment, cells were stimulated with the indicated stimuli.
24h later supernatants were harvested and IP-10 was measured by ELISA and the cellular expression of
IFN-β was determined on RNA level by qRT-PCR analysis.
A: IP-10 production after stimulation with transfected triphosphate RNA (50ng/well), VSV M51R
(MOI=10), Sendai virus (1:100). Data are shown as mean + SEM of n=3. B: qRT-PCR for IFN-β
after stimulation with triphosphate RNA (50ng/well). One representative experiment of three is shown.
C: qRT-PCR to calculate knockdown efficiency for the siRNAs used in A-B. Knockdown efficiency was
calculated as 1-(mRNA levels with specific siRNA/mRNA levels with control siRNA)x100%. One repre-
sentative experiment of three is shown. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 indicate significance levels
comparing CO4-treated cells and cells treated with targeting siRNA.
To rule out off-target effects of the used siRNAs, siRNAs with different binding sites within
the CRIF1 and RBM10 mRNAs were designed. To validate the control siRNA CO4 used
as the non-targeting negative control, a second control siRNA was produced that targets
firefly luciferase (GL2). Mammalian cells like 1205lu do not naturally express luciferase,
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but an overexpressed luciferase construct could effectively be silenced by it (not shown),
indicating it is a functional siRNA and valid control. Cells treated with this second set of
siRNAs however showed the same results as the first set of siRNAs after stimulation with
triphosphate RNA using IP-10 in the supernatant as readout (Figure 3.4 A, upper panel).
As a supposedly nuclear protein, CRIF1 might interfere with IP-10-induction on the pro-
motor level. Then it would be interesting to test if the observed effect is specific for IP-10
or also influences the induction of other cytokines triggered by RIG-I activation, such as
IL-6. However, if the observed phenotype is due to a specific interaction with RIG-I as the
initial pull-down assay suggested, it should influence all effector proteins of RIG-I signaling,
but not the signaling downstream of other PRR like, e.g., MDA5 or the Toll-like receptors.
Therefore, IP-10 and IL-6 induction triggered via MDA5-mediated recognition of poly(I:C)
was also tested in loss-of-function experiments with CRIF1 and RBM10 siRNA (Figure 3.4
B) and compared with cytokine production triggered by triphosphate RNA via RIG-I. In
the case of poly(I:C) stimulation, siRNA against RIG-I functions as a negative control as
RIG-I is not involved in the recognition of poly(I:C), while MAVS, the positive control,
acts as the downstream adaptor of both RIG-I and MDA5.
Figure 3.4: Depletion of CRIF1 by siRNAs with Different Binding Sites Leads to Reduced IP-10
and IL-6 Production in Response to RIG-I- and MDA5-Stimulation
5x103 1205lu melanoma cells per well were plated on a 96-well plate and treated twice, 24h apart, with
the indicated siRNAs. 48h after the first treatment, cells were stimulated with the indicated stimuli. 24h
later supernatants were harvested and IP-10 and IL-6 levels were measured by ELISA. A: IP-10 and IL-6
production after stimulation with transfected triphosphate RNA (100ng/well). Data are shown as means
+ SEM of n=3. B: IP-10 and IL-6 production after stimulation with transfected poly(I:C) (100ng/well).
Data are shown as means + SEM of n=3. *p ≤ 0.05, **p ≤ 0.01.,***p ≤ 0.001 indicate significance
levels comparing CO4-treated cells and cells treated with targeting siRNA.
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Both triphosphate RNA and poly(I:C) induce IL-6 as well as IP-10. Stimulation after
treatment with the non-targeting controls siCO4 and siGL2 produced similar levels of IP-10
and IL-6. Depleting RIG-I by siRNAs significantly lowered IP-10 and IL-6 induction in
triphosphate RNA-stimulated cells, but showed no effect on poly(I:C)-stimulated induction.
Depletion of MAVS lowered cytokine induction by RIG-I and MDA5 dependent stimuli.
Depletion of CRIF1 by siRNAs again strongly diminished both IP-10 and IL-6 production
after stimulation with either triphosphate RNA or poly(I:C).
This shows that depletion of CRIF1 does not exclusively influence RIG-I signaling, but
also influences MDA5 signaling and not only influences the induction of IFN, but also the
induction of inflammatory cytokines like IL-6.
3.3 CRIF1-Depleted Cells Are Viable and Do Not
Show Cell Cycle Arrest
Deficiency of CRIF1 was found to increase viral replication and to decrease cytokine pro-
duction by a so far unknown mechanism. As CRIF1 knockout mice die at an early stage
in embryonic development [67], cell death has to be ruled out as an explanation of the
observed anti-viral phenotype.
To test the influence of CRIF1-knockdown on cell viability, viability assays were performed
using the commercially available CellTiter-Blue Cell Viability Assay (Figure 3.5 A).
While viability was reduced to about 60% in all cells treated with lipofectamine and siRNA,
no significant difference could be detected among cells treated with control siRNA or
siRNAs depleting RIG-I, MAVS or CRIF1.
Transfection of siRNA is toxic to cells [81]. However, as control siRNA and CRIF1 siRNA
were equally toxic, cell death cannot explain the differences in viral replication and cytokine
induction seen before (Figure 3.2-3.4).
Deficiency of RBM10 showed a small reduction in cell viability. Possibly, some part of the
loss of cytokine release in knockdown cells can be attributed to this loss of viability, but it
cannot be said for certain if it explains the whole effect.
Apart from cell death, a role for CRIF1 in cell cycle modulation has also been described in
the literature [61]. As the single experiment underlining this claim shows an unusual cell
cycle status in the negative control, it was important for this study to see if this finding
could be replicated in the CRIF1-knockdown system and possibly explain the observed
effect.
Untreated 1205lu cells showed a ratio of about 60% of cells in G1 stage, 20% in S/G2 and
10% in the M phase. Neither cells depleted of CRIF1 nor cells depleted of RBM10 differed
more than 5 percentage points from this ratio.
All cells showed a ratio typical for asynchronous cells, so no cell cycle block as described
in [61] was found by depletion of CRIF1 in our setting.
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Figure 3.5: Viability and Cell Cycle Analysis of CRIF1 or RBM10 Depleted Cells
5x103 1205lu melanoma cells per well were plated on a 96-well plate and treated twice, 24h apart, with
the indicated siRNAs. A: 48h after the first treatment, cells were infected with VSV GFP M (MOI=10)
and cell viability was measured 24h later with CellTiter-Blue Cell Viability Assay (Promega). Error bars
indicate SEM (n=3), **p ≤ 0.01 indicate significance levels comparing CO4-treated cells and cells treated
with targeting siRNA. B: 24h after the second knockdown, cells were stained with the DNA marker PI
and DNA content was measured by flow cytometry to distinguish cell populations in the different cell
cycle stages. One representative experiment out of n=3 is shown.
3.4 CRIF1 Shows no Significant Effect on Infection
Rates with the Model DNA Virus MVA
Having observed a role for CRIF1 in RLH-mediated antiviral immunity, a further question
was whether this influence on the cellular defense status is specific for immunity against
RNA viruses or whether this is also observed in other viral infections. To test this, the
Modified vaccinia Ankara (MVA) virus was chosen as the model agent for infection assays.
MVA is a highly attenuated, replication-deficient and well established model DNA virus
and a genetically modified variant expressing GFP existed [70].
To find out whether the defect in antiviral immunity in CRIF1-knockdown cells extends
to DNA viruses, infection rates of MVA virus expressing GFP were monitored by flow
cytometry. Two types of assay were tested, an infection of 24h (Figure 3.6 A) or two
subsequent infections of 12h each to imitate a replication cycle of the non-reproductive
MVA virus (Figure 3.6 B). HEK293 cells which do not express functional RIG-I were used
in this assay to search for an RLH-independent effect of CRIF1 depletion. An siRNA
against IRF3 was chosen as a positive control.
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Figure 3.6: Depletion of CRIF1 does not Influence Infection Rates with MVA after Single or
Double Infection
HEK293 cells were depleted of the indicated proteins using RNA interference. Cells were treated twice
(24h apart) with siRNA or the non-targeting control CO4. The timeline of the experiments is indicated
above the panels. A: 48h after the first siRNA treatment, cells were infected with a GFP-expressing
MVA (MOI=3) for 24h. GFP-positive (=infected) cells were determined by flow cytometry. Data are
shown as mean + SEM of n=3. B: 48h after the first siRNA treatment, cells were infected twice with
MVA (MOI=1) for 12h each. GFP-positive (=infected) cells were determined by flow cytometry. Data
are shown as mean + SEM of n=3. *p ≤ 0.05, **p ≤ 0.01.,***p ≤ 0.001 indicate significance levels
comparing CO4-treated cells and cells treated with targeting siRNA.
Primary infection rates of the non-replicative MVA virus do not seem to change upon inhibi-
tion of IFN signaling (Figure 3.6 A). When mimicking replication with a second infection,
IRF3-knockdown cells showed an increased infection rate. CRIF1-knockdown, however,
had no such effect, indicating that facilitated viral replication after CRIF1-knockdown
does not occur after infection with DNA viruses like MVA.
3.5 Depletion of CRIF1 Leads to Enhanced TLR7 and
TLR9 Activation of NF-κB while Inhibiting RLH-
mediated Activation of ISGs
TLRs play an important role in the recognition of a great number of viruses, bacteria,
parasites and funghi. As CRIF1 was found to influence RLH signaling, it was tested if
CRIF1 also plays a role in the signaling pathways of other pattern recognition receptors.
For this, 1205lu cells depleted or not of CRIF1 by siRNAs were stimulated for 24h with
untransfected poly(I:C) for TLR3 stimulation, R848 for TLR7/8 stimulation, CpG ODN
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for TLR9 stimulation, lipopolysaccharid (LPS) for TLR4 stimulation, D-glutamyl-meso-
diaminopimelic acid (iE-DAP) for nucleotide-binding oligomerization domain-containing
protein 1 (NOD1) stimulation and transfected triphosphate RNA and poly(I:C) for RIG-I
and MDA5 stimulation, respectively. IP-10 in the supernatant was used as the readout
(Figure 3.7).
Figure 3.7: Depletion of CRIF1 Leads to Reduced IP-10 Production in Response to RIG-I-,
MDA5- and Possibly TLR3-Stimulation
5x103 1205lu melanoma cells per well were plated on a 96-well plate and treated twice, 24h hours apart,
with CRIF1-depleting siRNA or the non-targeting control CO4. 48h after the first treatment, cells were
stimulated with high and low concentrations of the following stimuli: untransfected poly(I:C) (200 and
100µg/mL), R848 (10 and 5µg/mL), CpG (3 and 1.5µg/mL), LPS (1 and 0.5µg/mL), iE-DAP (1:1000
and 1:2000), transfected triphosphate RNA and transfected poly(I:C) (each 200ng/well). After 24h,
supernatants were harvested and IP-10 levels were measured by ELISA. Data are shown as mean + SEM
of n=3.
This experiment showed that 1205lu cells do not induce IP-10 in response to TLR4,
TLR7/8, TLR9 or NOD1 stimulation, indicating that these cells are either not expressing
those receptors or are missing relevant signaling modules for those receptors. Therefore,
the same assay used to show the effect of CRIF1 on RLH signaling cannot be used to rule
out an influence on these signaling systems.
RIG-I, MDA5 and most likely TLR3-stimulation, however, produced a response which was
diminished strongly in the case of RIG-I activation and less for MDA5 and TLR3. As
TLR3 is activated by endosomal poly(I:C), whereas MDA5 is activated by cytoplasmic
poly(I:C), a cross-reaction cannot be ruled out completely. High amounts of uncomplexed
polyI:C are required to stimulate endosomal TLR3 and considering the effect of CRIF1
knockdown is less for uncomplexed than for complexed poly(I:C), it cannot be excluded
that uncomplexed poly(I:C) also to a certain extend activates MDA5 and the effect of
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CRIF1 depletion is only mediated via its effect on the MDA5 pathway.
Because of the limitations to evaluate the role of CRIF1 in TLR-signaling in our 1205Lu
cell model, a reporter assay using overexpressed TLR7 and 9 in HEK293 cells was used to
examine this question further.
For this, HEK293 cells stably overexpressing TLR7 or TLR9 and a luciferase reporter
controlled by the NF-κB promotor were assessed with or without prior depletion of CRIF1
for the activation of NF-κB after stimulation with CpG ODNs or R848, respectively (Figure
3.8).
Figure 3.8: Depletion of CRIF1 Increases NF-κB Promotor Activation in Response to TLR7-
and TLR9-Stimulation
1x104 HEK293 cells per well stably overexpressing TLR7 or TLR9 as well as a luciferase reporter controlled
by the NF-κB promotor were plated on 96-well plate and treated twice, 24h apart, with the indicated
siRNAs. 48h after the first treatment, cells were stimulated with A: 500ng R848 per well or B: 500ng
CpG per well. 24 hours later the NF-κB-dependent luciferase activity was determined in a luminescence
reader. Data present the unnormalized light counts per second as mean + SEM of n=3. ***p ≤ 0.001
indicate significance levels comparing CO4-treated cells and cells treated with targeting siRNA.
The HEK cell line expressing TLR7 showed a low baseline activation of the NF-κB pro-
motor that was strongly induced upon stimulation with R848. Cells treated with RBM10-
targeting siRNA showed the same level of activation as those treated with control siRNA,
while cells treated with the siRNA against CRIF1 showed an increased activation of NF-κB
(Figure 3.8 A).
Similarly, in the cell line expressing TLR9, cells treated with siRNA depleting CRIF1
showed a stronger inductione of NF-κB than those treated with control siRNA or siRNA
targeting RBM10 (Figure 3.8 B) In the TLR9-expressing cell line, a higher baseline activa-
tion of the NF-κB promotor and a weaker induction by the corresponding TLR9-stimulus
CpG could be seen (Figure 3.8 B).
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These results suggest that CRIF1 might not only play a role in RLH-signaling but also
influence TLR-signaling. However, it seems to play a different role here than in RLH-
signaling, as the effect is inverted and depletion of CRIF1 enhances the TLR-dependent
activation of NF-κB.
3.6 CRIF1 Exerts its Influence in RLH Signaling Up-
stream of TBK1 and Independent of the IFNAR-
dependent Feedback-loop
Loss-of-function assays have implicated a role of CRIF1 in RLH-dependent anti-viral im-
munity, but it remains unclear how and on what level of the signaling cascade CRIF1
influences the RLH pathway. As CRIF1 has been described to be a nuclear protein and
transcription factor cofactor [67], it might not exert its effect in the RNA recognition cas-
cade initiated by RIG-I as our initial pull-down screening suggested. Instead, it could also
influence IFN effector function as a cofactor downstream of the IFN feedback loop. To
determine where the inhibition occurs, the IFN feedback loop was blocked with siRNA
against IFNAR. Any protein whose knockdown would then still influence IP-10 induction
should be involved in signaling upstream of the loop.
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Figure 3.9: Depletion of CRIF1 Leads to Reduced IP-10 Production in Response to RIG-I
Stimulation after Blockade of the IFN Feedback Loop but not in Response to Overexpression
of TBK1
A: 5x103 1205lu melanoma cells per well were plated on a 96-well plate and transfected twice, 24h apart,
with equal amounts of siRNA targeting IFNAR or the non-targeting control CO4 together with siRNA
targeting either RIG-I or CRIF1 or control CO4. 48h after the first treatment, cells were stimulated with
triphosphate RNA (200ng/well). 24h later supernatants were harvested and IP-10 levels were measured
by ELISA. Data are shown as mean + SEM of two independent experiments. B: 5x103 1205lu melanoma
cells per well were plated on a 96-well plate and transfected with 50ng/well of an empty pcDNA5 plasmid
or a plasmid expressing TBK1 within the cells. After 12h, cells were treated twice, 24h apart, with siRNA.
48h after the first siRNA treatment, supernatants were harvested and IP-10 levels measured by ELISA.
Data are shown as mean + SEM of n=2.
As can be seen in Figure 3.9 A, blockade of the IFN feedback loop with an siRNA target-
ing IFNAR substantially diminished IP-10 production upon triphosphate RNA stimula-
tion. However, IP-10 levels were still reduced further by both siRNAs targeting RIG-I and
CRIF1. This indicates that CRIF1, like RIG-I, plays a role upstream of the IFN feedback
system.
As initially, CRIF1 was believed to be a nuclear protein, it was hypothesized to influ-
ence IFN production at a promotor level downstream of TBK1, the kinase responsible for
phosphorylation of IRF3 downstream of MAVS in the RLH signaling pathway.
To test this hypothesis, TBK1 was overexpressed in 1205Lu cells with CRIF1 either de-
pleted or not, thereby triggering the signaling pathway downstream of TBK1, and IP-10
levels were measured as the readout.
As seen in Figure 3.9 B, overexpression of TBK1 was sufficient to induce IP-10. However,
this induction was not influenced by depletion of CRIF1.
This assay indicates CRIF1 exerts its influence in the signaling pathway upstream of TBK1.
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3.7 CRIF1 Exerts its Influence Independently of Pre-
viously Described Interacting Proteins
In a different approach to identify the mechanism of the observed phenotype of increased
RNA virus replication in CRIF1-depleted cells, the effect of depleting proteins previously
reported to interact with CRIF1 was tested to see if they might influence cytokine induction
by RIG-I ligands like CRIF1 does. siRNAs were designed against the three proteins STAT3,
casein kinase II (CKII) and growth-arrest and DNA-damage inducible protein gamma
(GADD45γ), for which an interaction with CRIF1 has been described previously [61, 62,
67].
Figure 3.10: Depletion of CRIF1 Interacting Proteins does not Lead to Reduced IP-10 Produc-
tion in Response to RIG-I Stimulation to the Same Extent that Depletion of CRIF1 does
1205Lu cells were depleted of the indicated proteins using RNA interference. Cells were treated twice
(24h apart) with siRNA or the non-targeting control CO4. 48h after the first treatment, cells were
stimulated with triphosphate RNA (200ng/well). 24h later supernatants and cells were harvested. A:
IP-10 levels in the supernatant were measured by ELISA. Data are shown as mean + SEM of n=3.
B: qRT-PCR of the cells was used to determine the knockdown efficiency for the siRNAs used in A.
Knockdown efficiency was calculated as 1-(mRNA levels with specific siRNA/mRNA levels with control
siRNA)x100%. ***p ≤ 0.001 indicate significance levels comparing CO4-treated cells and cells treated
with targeting siRNA..
Neither knockdown of STAT3, CKII nor GADD45γ, however, inhibited cytokine induction
to the extend knockdown of RIG-I or CRIF1 did (Figure 3.10 A). Knockdown efficiencies
for the tested siRNAs were between 60 and 90% (Figure 3.10 B). For GADD45γ, no mRNA
could be detected in 1205Lu cells, so it is unlikely to be involved in the CRIF1 phenotype
observed in these cells.
These results suggest that CRIF1 exerts its influence through a mechanism independent
of previously reported CRIF1-interacting proteins.
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3.8 CRIF1 and RBM10 Expression does not seem to
be Significantly Induced upon Viral Infection
Many anti-viral genes are strongly upregulated during viral infection. Indeed, many anti-
viral proteins were identified because they were strongly induced by IFN in the course of
viral infection.
Figure 3.11: CRIF1 is Weakly Induced on mRNA Level After 36 Hours of VSV Infection
A: 1x105 HEK293 cells per well were plated on a 24-well plate and infected with VSV M51R at an
MOI=2. After the indicated time, cells were harvested and levels of the indicated mRNAs were measured
by qRT-PCR. Data are shown as mean + SEM of two independent experiments. B: 5x104 HEK293 cells
per well were plated on a 24-well plate and infected with VSV M51R at an MOI=3. After the indicated
time, cells were harvested and levels of the indicated mRNAs were measured by qRT-PCR. Data are
shown as mean + SEM of two independent experiments. C: 1x105 PBMCs per well were plated on a
24-well plate and infected with VSV M51R at an MOI=5. After the indicated time, cells were harvested
and levels of the indicated mRNAs were measured by qRT-PCR. Data are shown as mean + SEM of
three independent experiments. **p ≤ 0.01.,***p ≤ 0.001 indicate significance levels comparing cells
before and after stimulation.
To find out whether CRIF1 or RBM10 are induced upon viral infection, HEK293 cells
were infected with VSV and mRNA levels were measured over the following 48 hours. To
analyze possible differences between cell lines and primary cells, CRIF1 mRNA levels were
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also measured in PBMCs after stimulation with VSV.
While IFN-β and the known IFN-inducible gene RIG-I were strongly induced in HEK293
cells, no specific induction could be detected for RBM10 or CRIF1 mRNA within the first
24 hours (see Figure 3.11 A).
However, 36 and 48 hours after infection with VSV, an up to six-fold induction of CRIF1
could be observed in HEK293 cells on mRNA level (Figure 3.11 B).
In PBMCs, such an increase in mRNA levels could not be observed (Figure 3.11 C),
indicating that this response is either limited to cell lines in contrast to primary cells or to
tissue cells in contrast to immune cells.
For RBM10, levels do not seem to react to viral infection.
3.9 Overexpression of CRIF1 Does Not Enhance RLH
Signaling
Since loss of CRIF1 function diminishes cellular cytokine response to RLH stimulation, it
was tested if gain of function by overexpression of CRIF1 might in turn have an opposite
effect.
To do so, an untagged CRIF1 was overexpressed in 1205lu cells and cytokine response was
measured in cells stimulated or not with triphosphate RNA or poly(I:C). Overexpression
of untagged RIG-I, MAVS or MDA5 were used as positive controls, empty pcDNA5 vector
as negative control.
None of the transfected plasmids resulted in a significant stimulation of the cells without
an additional stimulus (data not shown). Both triphosphate RNA and poly(I:C) treatment
resulted in a strong induction of IP-10 and IL-6 which was significantly increased in cells
overexpressing MAVS or the corresponding RLH, but not in cells overexpressing CRIF1 or
RBM10 (figure 3.12).
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Figure 3.12: Overexpression of CRIF1 or RBM10 does not Enhance RLH-Mediated Cytokine
Induction
2x103 1205lu melanoma cells per well were plated on a 96-well plate and transfected with empty pcDNA5
vector or pcDNA5 vector expressing untagged RIG-I, MAVS, MDA5, RBM10 or CRIF1 within the cells.
After 48h, cells were stimulated with A: triphosphate RNA (25ng/well) or B: poly(I:C) (100ng/well).
After 24h supernatants were harvested and levels of IP-10 and IL-6 were measured by ELISA. The
timeline of the experiment is indicated above the panels. Data are shown as mean + SEM of n=3. *p
≤ 0.05, **p ≤ 0.01.,***p ≤ 0.001 indicate significance levels comparing cells treated with the empty
control vector to cells transfected with the indicated expression vector.
In the case of CRIF1, overexpression does not show the opposite phenotype of the loss-of-
function assays desribed before. This negative result does not allow any firm conclusions,
but is compatible with the interpretation that the endogenous expression of CRIF1 in
1205Lu does not seem limiting for RIG-I signaling.
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3.10 CRIF1 and RBM10 Co-immunoprecipitate with
Anti-flag Agarose Beads Independently of RIG-I
As CRIF1 and RBM10 were originally found by mass spectrometry in a screening assay
searching for RIG-I-interacting proteins in cells stimulated with VSV, co-immunoprecipitation
was repeated to confirm the specific interaction of CRIF1 with RIG-I by western blot.
For immunoprecipitation, HEK293 cells were used just as in the original screening assay.
These cells were transfected with either flag-tagged RIG-I or the empty control vector and
either RBM10 or myc-tagged CRIF1. After infection with VSV for 18h, immunoprecip-
itation was performed and the eluate was compared to the lysate used as input and the
supernatant by western blot (Figure 3.13).
Figure 3.13: Both CRIF1 and RBM10 Co-Immunoprecipitate with Anti-Flag Agarose Beads
Independently of RIG-I
2.5x106 HEK293 cells per condition were plated in a 10cm-dish and subsequently transfected with
plasmids expressing flag-tagged RIG-I, RBM10 together with myc-tagged CRIF1 or an empty control
vector to a total of 6µg DNA. After 24h, cells were infected with VSV at an MOI of 0.1. 18h later cells
were lysed on ice and the lysate was used as input for immunoprecipitation using anti-flag agarose beads.
Lysate, supernatant and eluate were immunostained by western blot using anti-flag antibody to stain
RIG-I, anti-myc antibody to stain CRIF1 and anti-RBM10 antibody respectively. The depicted results
are representative for three independent experiments.
As seen in Figure 3.13, RIG-I-flag was found in the lysate and eluate, but not in the
supernatant. RBM10 and CRIF1-myc could be seen in the lysate and supernatant of
transfected cells. Both were also found in the eluate of both RIG-I-flag expressing and
non-expressing cells.
The immunoprecipitation worked as all overexpressed RIG-I was pulled from the lysate
into the eluate, depleting the supernatant completely. However, although both RBM10 and
CRIF1 could be found in the immunoprecipitate eluted from anti-flag-antibodies in cells
overexpressing RIG-I-flag, surprisingly they could also be found in the immunoprecipitate
of cells not expressing RIG-I-flag (Figure 3.13). These results show that CRIF1 and RBM10
do not interact specifically with RIG-I, but in fact interact RIG-I-independently with anti-
flag-beads. They were not found in immunoprecipitation carried out with control IgG
beads (not shown), but seem to solely interact with anti-flag beads.
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3.11 CRIF1 is a Mitochondrial Protein That is Tar-
geted to Mitochondria by a Mitochondrial Tar-
geting Sequence at the N-terminus
In the literature, CRIF1 has been described as a nuclear protein [61, 63, 67] based on
observations using overexpressed tagged proteins. In our setting, we did not find functional
clues to support a nuclear localization. As the localization of a protein within the cell is
important for its function, we chose to examine the localization of CRIF1 using fluorescently
tagged constructs.
A plasmid containing CRIF1 fused to N-terminal GFP [77] and a plasmid containing CRIF1
fused to C-terminal mCherry, a red fluorescent protein, were used to visualize CRIF1 in
transfected 1205lu cells.
Both constructs were expressed by the cells and could be seen in live cell imaging. However,
the two differently tagged proteins localized differently: While n-terminally tagged GFP-
CRIF1 co-localized with the nuclear dye, c-terminally tagged CRIF1-mCherry was found
outside the nucleus (Figure 3.14 A), co-localizing with a mitochondrial dye (Figure 3.14
B).
These images show CRIF1 is localized differently depending on tagging. A construct tagged
at the N-terminus is transported to the nucleus, a C-terminally tagged one resides in the
mitochondria.
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A
B
CRIF1-mCherry mitochondrial stain nuclear stain merged
CRIF1-mCherry GFP-CRIF1 nuclear stain merged
Figure 3.14: Overexpressed CRIF1 is Localized in the Nucleus or Mitochondria Depending on
Tag Localization
3x104 1205lu cells were plated onto a glass bottom dish, transfected with 250ng p5-CRIF1-mCherry
alone or together with pEGFP-CRIF1-C3 for 48h and stained with Hoechst nuclear dye alone or together
with the mitochondrial stain MitoTracker R© Green FM (Invitrogen) before live cell confocal microscopy.
A: Confocal images of the intracellular localization of N-terminally tagged GFP-CRIF1 in relation to
CRIF1-mCherry and nuclear stain Hoechst. B: Confocal images of the intracellular localization of C-
terminally tagged CRIF1-mCherry compared to mitochondrial stain MitoTracker R© Green FM (Invitrogen)
and nuclear stain Hoechst.
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Given that CRIF1 has two different localizations depending on tagging which seemed to
be mutually exclusive, the question was where native protein localizes within the cell.
To address this question, CRIF1 was visualized in untransfected cells using immunofluo-
rescence.
a-CRIF1 mitochondrial stain nuclear stain merged
Figure 3.15: Native CRIF1 is Localized at the Mitochondria
5x104 1205Lu cells were plated on a microscope cover slip and subsequently stained with 100nM
MitoTracker R© Red CMXRos (Invitrogen). After methanol fixation, cells were stained with anti-CRIF1-
antibody and a green fluorescent secondary antibody before being stained with DAPI nuclear stain and
visualized by fluorescence microscopy.
As seen in Figure 3.15, immunofluorescently labeled endogenous CRIF1 shows a clear co-
localization with mitochondrial stains, not with the nuclear stain, leading to the conclusion
that native CRIF1 is localized mainly or exclusively in mitochondria.
As a mitochondrial localization was observed with both overexpressed and native protein,
the CRIF1 protein sequence was analyzed using the MitoProt algorithm [82] offered by the
Helmholtz Center Munich and a mitochondrial targeting sequence (MTS) was predicted
at amino acids 1-35 of the protein.
To test whether this N-terminal MTS was necessary for its mitochondrial localization, a
deletion mutant was created missing the first 34 amino acids after the methionine and
containing a fluorescent tag at the C-terminus.
Mitochondrial targeting signals are typically hydrophilic and positively charged sequences
contained in amino-terminal prepeptides [82]. If these properties in the MTS are necessary,
a point mutation changing a positively charged amino acid into a neutral one might impair
the mitochondrial localization. By switching the arginine (R) residue in position 26 to an
alanine (A), the localization of the protein could be studied with a reduced positive charge
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of the MTS.
Figure 3.16: A Missing or Mutated MTS Mislocalizes CRIF1 to the Nucleus or Cytoplasm
A: Schematic representation showing the proposed mitochondrial (MTS) and nuclear (NLS) localization
sequences of wildtype CRIF1 and the sequence changes in the δMTS and R26A mutant. B: 1205lu cells
were transfected with the MTS deletion mutant p5-CRIF1-δMTS-mCherry for 24h, then treated with
Hoechst nuclear stain and viewed live under a confocal microscope. B: 1205lu cells were transfected with
the MTS point mutant p5-CRIF1-R26A-mCherry for 24h, then treated with Hoechst nuclear stain and
viewed live under a confocal microscope.
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Plasmids expressing the MTS deletion mutant δMTS or the point mutation R26A fused
to a c-terminal red fluorescent tag were expressed in 1205lu cells and analyzed by live cell
fluorescence microscopy.
As seen in Figure 3.16 A, the overexpressed MTS deletion mutant was localized in the
nucleus and in the cytoplasm of all transfected cells. CRIF1 with the R26A mutation
was partly imported into mitochondria and partly expressed in the cytoplasm and nucleus
(Figure 3.16 B).
This shows that deletion of the putative MTS results in a complete loss of the mitochondrial
localization phenotype and a single amino acid change is enough to disrupt mitochondrial
localization in some cells. These observations indicate that the MTS is responsible for tar-
geting CRIF1 into mitochondria and positive charge is necessary for efficient translocation.
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Chapter 4
Discussion
4.1 Overview of the Experimental Results
CRIF1 and RBM10 were previously identified in a mass spectrometry-based screen search-
ing for proteins interacting with the innate pattern recognition receptor and sensor for viral
RNA RIG-I. The present study further examined a potential role for CRIF1 and RBM10
in antiviral signaling. The main findings were the following:
• In a cell culture model, depletion of CRIF1 by RNA interference resulted in an
increased infection and replication rate of RNA viruses (VSV, Sendai Virus). No
such effect could be observed upon infection with a DNA virus (MVA)
• Depletion of CRIF1 led to a decrease in RLH-dependent IFN-, IP-10- and IL-6-
induction, both upon activation of RIG-I and MDA5. Conversely, TLR-dependent
NF-κB activation did not show a reduction upon depletion of CRIF1, instead, a slight
increase could be seen.
• The decrease in RLH-induced cytokine-production after depletion of CRIF1 was only
observable when the stimulation occurred upstream of TBK1, and occurred indepen-
dently of the positive-feedback loop active in interferon signaling.
• Overexpression of CRIF1 did not influence cytokine induction upon RLH stimulation,
or viral infection rates (not shown).
• CRIF1 does not directly interact with RIG-I but unspecifically binds to anti-FLAG
agarose beads
• Endogenous CRIF1 is localized to mitochondria via its N-terminal MTS. Truncation,
loss of charge or blockade of this MTS by mutation or N-terminal tagging result in
mislocalization to the cytoplasm or the nucleus.
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4.2 Methodological Aspects of the Observed CRIF1
Function
CRIF1 knockdown cells showed a highly increased viral replication rate in different types
of assays, e.g., flow cytometry or plaque assay. Cytokine response to different stimuli trig-
gering RIG-I or MDA5 activation was diminished. Can these results be trusted considering
they rely solely on RNA interference experiments?
siRNA-based loss of function assays present two types of problems that can contest their
validity: sequence dependent off target effects and immune activation by recognition of the
introduced foreign RNA. Both can never be completely excluded, but can be minimized
and controlled for by strategies employed in this study.
Sequence-dependent off-target effects occur when an siRNA binds to and induces the cleav-
age of other mRNA than the one it was designed for. To reduce this risk, all siRNA se-
quences were blasted against the NCBI human transcript database before they were used
to ensure they only had one single expected target. Also, several siRNAs with different,
non-overlapping sequences were designed for each target. These different sequences are
likely to differ in their off-target effects, so if the same effect is seen with different siRNAs
against the same mRNA, an off-target effect as explanation becomes less likely. All three
different CRIF1 siRNAs showed the same phenotype alongside a robust knockdown of
CRIF1 on mRNA level. This indicates the observed effect is most likely target-specific.
In addition to unwanted targeting of other mRNAs, siRNAs, like all dsRNAs, have the
capability to potently activate the innate immune system through PRRs and produce nu-
merous unwanted effects. PRRs capable of recognizing and responding to foreign RNA
include TLR3, 7 and 8 as well as the cytoplasmic sensors PKR, MDA5 and RIG-I [83].
Epithelial cells like 1205lu used in this work do not routinely express TLR7 and 8, as
could also be seen in the screening assay presented in figure 3.7. PKR is expressed in
most mammalian cells, but responds to longer strands of RNA than siRNA. TLR3 can be
expressed on the cell surface and endosome of epithelial cells, where it should theoretically
not come into contact with siRNA transfected into the cytoplasm. Cytosolic RIG-I recog-
nizes uncapped triphosphate RNA and blunt RNA, so 5’ monophosphate siRNA with a 3’
dTdT overhang was used to avoid RIG-I stimulation. To control for stimulation of TLR3
or RIG-I that might have occurred, cytokine levels of unstimulated siRNA treated cells
were also monitored, and no induction of IP-10 or IL-6 by the siRNAs used in this work
could be detected.
Another drawback of the available methods was the lack of a reliable system to test the
influence of CRIF1 on TLR-signaling, as the readout in this system was NF-κB activation,
whereas for RLH signaling, it was IRF-mediated IP-10 induction. The difference observed
upon stimulation of RLH-and TLR-signaling after depletion of CRIF1 could therefore be
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due to an impact on IRF versus NF-κB signaling. However, RLH-mediated induction of
IL-6, which is mostly NF-κB-dependent, showed a similar reduction in response to CRIF1
depletion as induction of IP-10 did. Therefore, it is likely that it is an influence on RLH- in
contrast to TLR-signaling that mediates the different phenotypes upon CRIF1 depletion
observed in our assays.
In conclusion, appropriate measures were taken to avoid siRNA-related artefacts since no
better system to study CRIF1 function was available. Assays controlled in this way showed
loss of CRIF1 function has an impact on viral replication and cytokine response in human
epithelial cells.
Later experiments by Simon Hirschberger, another member of this working group, strength-
ened the validity of these findings: using an inducible murine knockout system [84], he
also observed a repression of anti-viral signaling in CRIF1−/− mouse embryonic fibrob-
lasts (MEFs).
4.3 CRIF1 Function in Antiviral Immunity: the Role
of Mitochondria
Open questions remain concerning the exact mechanism of this anti-viral function of
CRIF1. Evidence suggests that there is a direct effect on the cytosolic part of the sig-
naling cascade activated by RLHs, not on the antiviral response initiated by interferon
after binding to IFNAR. Taken together with our findings regarding the strict mitochon-
drial localization of native CRIF1, it seems likely that CRIF1 influences RLH signaling on
the level of mitochondria.
The essential role of mitochondria for antiviral immunity is currently being discovered
and many mitochondrial functions and characteristics have been shown to influence RLH-
dependent signaling. The first link to be described was MAVS, the central adapter protein
located on the outer mitochondrial membrane. A direct interaction between CRIF1 and
MAVS might be possible, although the MTS classifies CRIF1 as probably being a matrix
protein, thus not in contact with the outer membrane. Subfractioning studies done by our
group (data not shown) support this localization.
Other mitochondrial features influencing antiviral signaling include a stable membrane
potential [37], intact mitochondrial fusion [55] and the production of ROS [58, 59]. Exactly
how these factors exert their influence and how they might be regulated by the cell to
modulate antiviral signaling is not described well yet. The influence of CRIF1 on antiviral
signaling could be mediated by any or several of these mechanisms.
Further research will be needed to examine this effect and to determine whether it is
a specific antiviral function mediated by CRIF1 or a general mitochondrial defect that
produces the effect.
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4.4 RBM10 and Anti-viral Immunity
RBM10 was found alongside CRIF1 and, as an RNA binding protein, seemed a promising
candidate in RNA-induced anti-viral signaling. However, loss of function assays did not
show a reproducibly convincing influence on viral infection rate. Cytokine induction was
repressed in knockdown cells, although RBM10 siRNA 1 and 2 differed in the extent of
repression while knockdown efficiency was similar.
Similar to CRIF1, RBM10 was shown to interact with anti-flag beads instead of interacting
specifically with RIG-I.
Taken together, there is some evidence from this study that RBM10 might play a role in
RLH-mediated antiviral signaling. These results, however, were not always consistent in
different types of assays and suffer from the limited validity of siRNA-based knockdown
experiments. As no other system was available to us to study RBM10 function, the project
was discontinued and efforts were focused on CRIF1 as the more promising candidate.
4.5 Interpretation of the Experimental Results with
Regard to Current Literature
4.5.1 Described Functions of Nuclear CRIF1
Reports on CRIF1 function so far have been highly controversial.
Chung et al. first described CRIF1 as an interactor of the cell cycle modulator GADD45γ,
which is also known as CR6, and hence named it cytokine-responsive protein CR6-interacting
factor 1 [61]. This interaction was discovered by yeast two-hybrid screens and confirmed
by immunoprecipitation of in-vitro translated CRIF1 using GADD45 proteins as bait as
well as immunoprecipitation of myc-CRIF1 in mammalian cells. Hypothesizing a func-
tion in cell cycle regulation, they show that recombinant CRIF1 inhibits kinase activity
of immunoprecipitated Cdc2-cyclin B1 and Cdk2-cyclin E, two cyclin-dependent kinases
involved in cell cycle regulation. They also see a block of G1 to S phase progression in NIH
3T3 mouse embryo fibroblast cells upon overexpression of flag-CRIF1, which also decreases
Rb phosphorylation in a manner reversible by CRIF1 siRNA.
Two years later, the same group described a functional interaction between CRIF1 and
NUR77, a transcription factor involved in regulation of the hypothalamic-pituitary-adrenal
axis [63]. This interaction was also discovered by yeast two-hybrid assay and confirmed
by GST pulldown and immunoprecipitation of overexpressed GFP-CRIF1. In their assays,
overexpressed flag-CRIF1 inhibits NUR77 transactivation and transcriptional activity in
a manner partially reversible by siRNA. HEK293 cells overexpressing GFP-CRIF1 show
a mild increase of cells in G1 phase and an inhibition of NUR77 dependent cell cycle
progression.
After another two years, the same group published an interaction between CRIF1 and
cell cycle regulator CKII seen by yeast two-hybrid assays, in-vitro Ni-pulldown assays and
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immunoprecipitation of overexpressed myc-CRIF1 in HeLa cells [62]. They show CRIF1 is
phosphorylated by CKII in vitro at serine residue 221. Upon overexpression of flag-CRIF1,
COS7 monkey fibroblast cells show no change in cell proliferation, while overexpressing
flag-CRIF1 with a mutation of serine 221 to glutamic acid, which is supposed to mimic
a phosphorylated serine, leads to an increased proliferation rate. This contradiction to
previous reports stating CRIF1 inhibits cell cycle progression and cell proliferation was
explained as being due to different cell lines.
In the subsequent year, Suh et al. described how ”CRIF1 represses the transactivation of
androgen receptor by direct interaction” [64]. Again, their results are mainly obtained by
overexpression of flag-CRIF1.
All these publications rely on overexpression of N-terminally tagged CRIF1 to describe
interactions or functional characteristics. Considering the localization in different cellular
compartments of native and N-terminally tagged CRIF1 as seen in this work, it is ques-
tionable how many of these described interactions have functional implications in vivo.
In 2008, Kwon et al. published CRIF1 to be a transcriptional co-activator of STAT3
[67]. In their assays, overexpression of HA-CRIF1 increases the transcriptional activity
of overexpressed STAT3. This publication is the first to describe CRIF1 knockout mice,
which show defective proliferation and massive apoptosis and die around embryonic day
E6.5. The authors trace the onset of this phenotype to the degradation of residual ma-
ternal CRIF1 mRNA during blastocyst stage. Investigating cultured CRIF1 blastocyst
cells, they find decreased expression of STAT3 target genes shortly before they die in cul-
ture. Conditional knockout of CRIF1 induced by infection with a Cre-bearing viral MSCV
vector showed a reduced induction of STAT3 target genes by oncostatin stimulation and
abolished activity of constitutively active STAT3-c in CRIF1 knockout MEFs. Being ob-
served in knockout cells, these results are more reliable than overexpression of a tagged
and possibly mislocalized protein. However, these cells die soon after the measurements
are taken, so a decreased transcription might also be due to impending cell death.
In a different publication, Kwon et al. find intestinal epithelium-specific CRIF1 knock-
out results in perinatal lethality displaying alterations of tissue architecture in the small
intestine and abnormal differentiation of absorptive enterocytes [66]. They attribute this
phenotype to a defect in Elf3-mediated differentiation of intestinal epithelium, but instead
of using their knockout system to reinforce that claim, overexpressed HA-tagged CRIF1 is
used for interaction and functional studies.
Similarly, Kang et al. use flag-tagged CRIF1 to show that oxidative stress response protein
NRF2 levels are decreased upon overexpression of CRIF1 [65]. They use flag-NRF2 as bait
in an anti-flag immunoprecipitation controlled with IgG beads and find CRIF1 in the elu-
ate. As the work presented here shows CRIF1 can bind to anti-flag-beads independently
of the bait, it is not sure whether there is a direct interaction between CRIF1 and NRF2
in vivo.
66 4. Discussion
4.5.2 Localization of CRIF1
Alongside different functions of CRIF1, different localizations were hypothesized and evi-
dence was found for each of them.
A nuclear localization of the protein was claimed [61, 63, 67, 62] as it was seen in this
study by overexpression of the N-terminally tagged protein.
In contrast, using immunohistochemistry with rabbit CRIF1 antiserum, Chung et al. see
CRIF1 expression in the nucleus and cytoplasm of adrenal cortex and thyroid epithelial
cells [61]. Due to low magnification and resolution, it cannot be deduced whether these
images show a cytoplasmic or mitochondrial localization. Similar results are obtained by
Kang et al., who use a monoclonal CRIF1 antibody and see both a nuclear and cytoplasmic
localization [65]. Interestingly, their stain is not homogenous, as the stain of cytoplasmic
proteins tends to be, but is instead freckled and forms networks compatible with a mito-
chondrial localization. The nucleus shows less staining in their images, but is not excluded
completely as we see it in our settings.
During the course of the experimental work presented here, a new publication dealt with
the subject of different localizations extensively [84]. Kim et al. show a nuclear localization
of N-terminally tagged CRIF1 in contrast to C-terminally tagged CRIF1 which is localized
predominantly in the mitochondria. Some cells in their setting also contain C-terminally
tagged CRIF1 in the nucleus, a localization we also saw when overexpression levels were
very high (data not shown). To resolve this conflict and examine the localization of na-
tive protein, they use immunohistochemistry. Interestingly, they describe their findings
as localized to the ”cytoplasm in all cells, with approximately 10% of cells also showing
staining in both the mitochondria and the nucleus” [84], while their figure shows a clear
and exclusive mitochondrial stain in all cells. This and the following subcellular fractioning
confirms our finding of CRIF1 as a mitochondrial protein.
The same publication also describes a 35aa sequence at the N-terminus which, if deleted,
results in a nuclear localization. If this sequence is added at the N-terminus of an N-
terminal GFP-tag, the resulting protein is localized exclusively to mitochondria. Thus,
our finding that an N-terminal MTS is responsible for the mitochondrial localization of
CRIF1 is confirmed by this publication.
So is the answer simply that CRIF1 is a mitochondrial protein, and all nuclear observations
were based on artefacts? Our results using rabbit anti-CRIF1 antibody in 1205lu cells and
Kim et al. using goat anti-CRIF1 antibody in HeLa cells certainly suggest the same, and
offer an explanation for earlier observations using tagged and overexpressed CRIF1. But
why is there a nuclear localization signal (NLS) conserved near the C-terminus and func-
tional the moment mitochondrial localization is blocked?
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Dual targeting of mitochondrial proteins is not an uncommon phenomenon [85]. Compe-
tition between two targeting signals can occur, and inaccessibility of a signal by folding,
protein binding or post-translational modification of the distributed polypeptide can direct
a protein to one location or the other. An incomplete import or retrograde translocation
by membrane leakage or protein export from organelles can also occur [86]. Thus, one
could speculate on a differential localization of CRIF1 in the cell depending on stimula-
tion, e.g. during apoptosis when mitochondria become leaky, to perform different functions
in mitochondria or nuclei.
Chung et al. see a nuclear location of CRIF1 in primary tissue using anti-CRIF1 anti-
serum [87]. Is staining of CRIF1 dependent on the cell or tissue type, or on the antibody
used? Many questions about the location of this essential yet elusive protein remain to be
answered.
4.5.3 Functions of Mitochondrial CRIF1
In their recent paper, Kim et al. not only show a mitochondrial localization of CRIF1, but
examine its function elaborately using CRIF1 knockout MEFs and brain-specific knockout
mice [84].
These knockout animals exhibited reduced lifespans as well as locomotion disabilities due
to neurodegeneration in the hippocampus and cerebral cortex. Mitochondria in these ar-
eas displayed morphological abnormalities including loss of electron-dense material from
the matrix and distorted or reduced number of christae. Tracing this degeneration to
protein levels, CRIF1 knockout mice showed reduced levels of oxidative phosphoryla-
tion (OXPHOS) complexes I and IV.
To study a mitochondrial function of CRIF1, CRIF1−/flox MEFs were infected with a
retrovirus expressing Cre-recombinase to obtain CRIF1 knockout MEFs. Oxygen con-
sumption rates in these knockout MEFs were drastically decreased compared to wildtype
MEFs and did not respond to treatment with chemical inhibitors of mitochondrial respi-
ratory chains. Mitochondrial membrane potential measured with JC-1 was reduced and
superoxide levels were elevated. This suggests mitochondria lacking CRIF1 are depolarized
and dysfunctional.
ATP levels in CRIF1 knockout cells were normal in high-glucose medium, but decreased
when grown in glucose-free medium compared to wildtype cells, indicating these cells rely
on glycolysis for ATP production. Enzyme activity of OXPHOS complexes I, III, IV and
V was markedly reduced in CRIF1 knockout MEFs, and their mitochondria showed struc-
tural abnormalities consistent with impaired OXPHOS complexes. Isolated mitochondria
showed lower levels of OXPHOS subunits of complexes I, III and IV originating from both
mitochondrial and nuclear genomes while transcripts of these proteins were at a similar
level as in wildtype cells. As the formation of respiratory complexes and supercomplexes
was also impaired in CRIF1 knockout cells, the authors concluded CRIF1 functions in the
68 4. Discussion
posttranslational biogenesis of OXPHOS complexes.
To pin down the role of CRIF1 in the mitoribosomal biogenesis of OXPHOS complexes,
gradient sedimentation analysis was performed and CRIF1 was found to co-migrate with
assembled 55S mitoribosomes and with the 39S large ribosomal subunits. As CRIF1 knock-
out MEFs showed a decrease in assembled 55S mitoribosomes while both subunits by
themselves were assembled similarly to wildtype cells, it was hypothesized that CRIF1 is
necessary for intersubunit assembly.
Pulse-chase assays showed a reduced protein synthesis in CRIF1 knockout cells and or-
ganelle translation assays revealed CRIF1 knockout mitochondria produced reduced amounts
and aberrant patterns of nascent translation products. In addition to these impaired syn-
thetic activities, CRIF1 knockout mitochondria also showed significantly less membrane
embedded and more soluble, extractable proteins compared to mitochondria expressing
CRIF1, suggesting that the integration of translation products into the inner mitochon-
drial membrane also depends on CRIF1.
Using immunoprecipitation, native CRIF1 was found to interact with large mitoribosomal
subunits and molecular chaperones as well as several nascent OXPHOS polypeptides.
The authors conclude CRIF1 is essential for the synthesis and insertion of nascent OXPHOS
polypeptides into the inner mitochondrial membrane. Indeed, the reduced levels of OXPHOS
subunits could be rescued by expressing CRIF1-HA within the knockout cells. HA-CRIF1,
which localizes to the nucleus, did not alter expression of OXPHOS subunits in CRIF1
knockout cells, verifying it is mitochondrial CRIF1 that produces the observed knockout
phenotype.
Figure 4.1: CRIF1 in Mitoribosomal Synthesis of OXPHOS Polypeptides
Schematic representation of CRIF1 function in mitoribosomal synthesis of OXPHOS polypeptides (from
[84]).
Figure 4.1 summarizes how Kim et al. hypothesize CRIF1 to be involved in the synthe-
sis and insertion of nascent OXPHOS polypeptides into the inner mitochondrial membrane.
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Based on their findings on the mitochondrial function of CRIF1, the same group studied
the mitochondrial defects produced by CRIF1 insufficiency in adipose tissue and cardiomy-
ocytes.
Using CRIF1 haploinsufficient adipocytes, they find increased ROS production and a
chemokine dysregulation [87]. Interestingly, they report an increase in IP-10 levels in
response to CRIF1 siRNA treatment in otherwise unstimulated cells. It remains to be seen
if this contrast to our findings is due to different cell lines or possibly a stimulatory effect
of the siRNA. Their findings based on CRIF1 knockout cells, however, have to be viewed
critically with regard to immune signaling as there is a genomic overlap between CRIF1
and the untranslated region of UV excision repair protein RAD23, which has been shown to
negatively regulate antiviral signaling [88]. In our studies, we find a decreased expression
of RAD23 in CRIF1f/f cells, possibly explaining a difference in immune activation in these
cells.
Using the same conditional knockout system of CRIF1 in cardiomyocytes, Shin et al. show
a fragmented mitochondrial network with a lack of christae and an increased mitochondrial
membrane potential followed by a loss of membrane potential after several days [89].
In conclusion, CRIF1 seems to influence mitochondrial ROS production, dynamics and
membrane potential.
In later experiments, our group could also show that CRIF1 knockout MEFs had a de-
creased mitochondrial membrane potential which has been shown to be critical for MAVS
activation and signaling [37]. A decreased mitochondrial membrane potential in CRIF1-
depleted cells could thus explain the decrease in RLH-dependent signaling we observed.
In contrast, ROS production has been linked to increased TLR signaling [90, 91] and NF-κB
activation [92]. Hence, the increase in NF-κB activation we see upon TLR stimulation in
CRIF1-depleted cells could be due to an increased ROS production, whereas mitochondrial
membrane potential is not essential here.
Figure 4.2 summarizes the putative role of CRIF1 in anti-viral signaling.
4.5.4 CRIF1 in Health and Disease
Based on this work, CRIF1 can be used to modify and study the role of early mitochondrial
damage in the context of antiviral signaling, but its application is not limited to this.
Recently, mitochondrial dysfunction has been shown to be essential in the development
of various diseases such as diabetes [93], atherosclerosis [94] and ischemia reperfusion in-
jury [95], cancer [96] and ageing [97], as well as various neurodegenerative diseases like
Parkinson’s, Huntington’s, Alzheimer’s disease, epilepsy and Friedreich ataxia [98], often
in conjunction with innate immune signaling, as in liver cirrhosis [90].
Here, conditional CRIF1 knockout cells might provide a model to study pathogenetic and
therapeutic aspects, as it was done with cardiomyopathy [89].
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Figure 4.2: Putative Influence of CRIF1 in Antiviral Signaling
CRIF1 localized in the mitochondria and involved in the production and membrane-insertion of proteins
translated in the mitochondria including the oxphos-complexes of the respiratory chain might influence
RLH signaling directly via MAVS, by influencing mitochondrial membrane potential, dynamics or ROS
production or through an as yet unknown mechanism (adapted from [38]).
Summary
RIG-I-like helicases are ubiquitously expressed pattern recognition receptors of the innate
immune system that are indispensable for sensing the presence of replicating viruses. They
are activated by viral RNA to induce a precisely modulated signaling cascade inducing an
antiviral gene program that helps the infected cell to resist viral replication and dissemi-
nation.
In an effort to identify new regulators of the RIG-I pathway, proteins that co-immuno-
precipitated with overexpressed RIG-I-FLAG in VSV-infected cells were identified by mass
spectrometry. In these screening experiments CRIF1 and RBM10 were identified as poten-
tial RIG-I interacting proteins. The aim of the present study was to investigate if CRIF1
or RBM10 indeed had a function in antiviral immunity and if so, by what mechanism.
In a cell culture model depletion of CRIF1 using RNA interference resulted in an increased
infection and replication rate by RNA viruses (VSV, Sendai Virus). No such effect could
be observed upon infection with a DNA virus (MVA). Mechanistically, RIG-I- and MDA5-
dependent IFN-, IP-10- and IL-6-induction was diminished upon depletion of CRIF1, while
a mild increase in TLR-dependent NF-κB activation could be observed. The interaction of
CRIF1 with the RLH-dependent antiviral signaling cascade seemed to occur upstream of
TBK1, but downstream of RIG-I, as a direct interaction between CRIF1 and RIG-I could
not be established. Our experiments suggest CRIF1 influences antiviral signaling on the
level of MAVS, the common adapter of RLH located in the outer mitochondrial membrane.
Previous reports described CRIF1 as a nuclear protein. In contrast, this study found CRIF1
to be localized exclusively to the mitochondria by an N-terminal mitochondrial targeting
sequence, whereas nuclear localization occurred only as an artefact upon overexpression or
N-terminal tagging of the protein.
Mitochondria play an essential role in antiviral signaling via the central adaptor protein
MAVS and mitochondria-derived reactive oxygen species, mitochondrial membrane poten-
tial and dynamics have all been described to influence RLH signaling.
Our data suggests CRIF1 influences RLH signaling at the level of mitochondria. Further
research will be needed to determine the exact mechanisms how CRIF1-induced changes
in mitochondrial function lead to the observed effects on antiviral signaling.
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Zusammenfassung
RIG-I-like Helikasen sind ubiquita¨re Rezeptoren, die fu¨r die Erkennung sich vermehren-
der Viren unabdingbar sind. Nach ihrer Aktivierung durch virale RNA induzieren sie
eine genau modulierte Signalkaskade, welche ein genetisches Programm aktiviert, das der
infizierten Zelle hilft, Replikation und Ausbreitung des Virus zu verhindern.
Um neue Einflussfaktoren auf die RIG-I-Signalkaskade zu ermitteln, wurden Proteine
per Massenspektrometrie identifiziert, welche mit u¨berexprimiertem RIG-I-flag in VSV-
infizierten Zellen koimmunprezipitieren. In diesen Screeninguntersuchungen wurden CRIF1
und RBM10 als potentielle, mit RIG-I interagierende Proteine identifiziert. Ziel der vor-
liegenden Studie war es nun, herauszufinden, ob CRIF1 und RBM10 einen Einfluss auf die
Virusabwehr haben, und wenn ja, u¨ber welchen Mechanismus.
In einem Zellkulturmodell wurde CRIF1 mittels RNA-Interferenz depletiert. Hierdurch
kam es zu einer erho¨hten Infektions- und Replikationsrate von RNA-Viren (VSV, Sendai
Virus). Eine Infektion mit einem DNA-Virus (MVA) zeigte keinen solchen Effekt. Mech-
anistisch war die RIG-I- und MDA5-abha¨ngige IFN-, IP-10- und IL-6-Induktion nach De-
pletion von CRIF1 reduziert, wa¨hrend die TLR-abha¨ngige Aktivierung von NF-κB etwas
erho¨ht wurde. Die Interaktion von CRIF1 mit der RLH-Signalkaskade schien oberhalb
von TBK1, jedoch unterhalb von RIG-I stattzufinden. Eine direkte Interaktion zwischen
CRIF1 und RIG-I konnte nicht besta¨tigt werden. Unsere Experimente legen stattdessen
nahe, dass CRIF1 die antivirale Signalkaskade auf der Ebene von MAVS als gemeinsamem
Adaptermoleku¨l der RLH auf der a¨ußeren Mitochondrienmembran beeinflusst.
Fru¨here Vero¨ffentlichungen beschrieben CRIF1 als nuklea¨res Protein. Wir konnten dagegen
zeigen, dass CRIF1 durch eine n-terminale Lokalisierungssequenz ausschließlich in Mito-
chondrien lokalisiert ist und die Lokalisation im Kern lediglich als Artefakt durch U¨berex-
pression oder N-terminales tagging entsteht.
Mitochondrien spielen mit dem Adapterprotein MAVS in der a¨ußeren Membran eine es-
senzielle Rolle als antivirale Signalplattformen. Mitochondriale reactive oxygen species,
das mitochondriale Membranpotential und die Dynamik von Aufbau und Fusion von Mi-
tochondrien sind als Einflussfaktoren der antiviralen Signaltransduktion u¨ber RIG-I-like
Helikasen beschrieben.
Unsere Ergebnisse lassen vermuten, dass CRIF1 einen Einfluss auf die antivirale Signal-
transduktion auf der Ebene der Mitochondrien ausu¨bt. Weitere Untersuchungen wer-
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den no¨tig sein, um den genauen Mechanismus zu beschreiben, u¨ber den CRIF1-bedingte
Vera¨nderungen der mitochondrialen Funktion die beobachteten Effekte auf die antivirale
Signalantwort verursachen.
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